compositions and methods for therapy of cystic fibrosis and other conditions are provided. The compositions comprise one or more compounds such as flavones and/or isoflavones capable of stimulating chloride transport in epithelial tissues. Therapeutic methods involve the administration (e.g., orally or via inhalation) of such compositions to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of chloride transport.
|
23. A method for enhancing chloride transport in epithelial cells, comprising contacting epithelial cells with genistein, wherein the epithelial cells produce a mutated cftr protein.
3. A method for enhancing chloride transport in epithelial cells, comprising contacting epithelial cells with a compound selected from the group consisting of reservatrol, ascorbic acid, ascorbate salts and dehydroascorbic acid.
28. A method for enhancing chloride transport in epithelial cells, comprising contacting epithelial cells with genistein and a compound selected from the group consisting of reservatrol, ascorbic acid, ascorbate salts and dehydroascorbic acid.
29. A method for increasing chloride ion conductance in airway epithelial cells of a patient afflicted with cystic fibrosis, wherein the patient's cftr protein has a mutation at position 551, the method comprising administering to a mammal one or more compounds selected from the group consisting of flavones and isoflavones, wherein the compound is capable of stimulating chloride secretion.
32. A pharmaceutical composition for treatment of cystic fibrosis, comprising:
(a) one or more flavones or isoflavones capable of stimulating chloride secretion; (b) one or more of: (i) a compound that increases expression of a cftr in an epithelial cell; and/or (ii) a chemical chaperone that increases trafficking of a cftr to a plasma membrane in an epithelial cell; and (c) a physiologically acceptable carrier.
1. A method for enhancing chloride transport in epithelial cells, comprising contacting epithelial cells with a compound capable of stimulating chloride transport, wherein the compound is not genistein and wherein the compound is:
(a) a polyphene compound having the formula: ##STR9## wherein carbon atoms at positions 2, 3, 5, 6, 7, 8, 2', 3', 4', 5' and 6' are bonded to a moiety independently selected from the group consisting of hydrogen atoms, hydroxyl groups and methoxyl groups, and wherein X is a single bond or a double bond; or (b) a stereoisomer of any of the foregoing polyphenolic compounds.
2. A method according to
4. A method according to
11. A method according to
12. A method according to
13. A method according to
14. A method according to
15. A method according to
16. A method according to
17. A method according to
18. A method according to
19. A method according to
20. A method according to
21. A method according to
25. A method according to
26. A method according to
27. A method according to
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a continuation-in-part of U.S. Ser. No. 08/951,912, filed Oct. 16, 1997.
The present invention relates generally to the treatment of cystic fibrosis. The invention is more particularly related to compositions comprising one or more compounds such as flavones and/or isoflavones, which may be used to activate chloride transport (i.e., absorption and/or secretion) in epithelial tissues of the airways, the intestine, the pancreas and other exocrine glands, and for cystic fibrosis therapy.
Cystic fibrosis is a lethal genetic disease afflicting approximately 30,000 individuals in the United States. Approximately 1 in 2500 Caucasians is born with the disease, making it the most common lethal, recessively inherited disease in that population.
Cystic fibrosis affects the secretory epithelia of a variety of tissues, altering the transport of water, salt and other solutes into and out of the blood stream. In particular, the ability of epithelial cells in the airways, pancreas and other tissues to transport chloride ions, and accompanying sodium and water, is severely reduced in cystic fibrosis patients, resulting in respiratory, pancreatic and intestinal ailments. The principle clinical manifestation of cystic fibrosis is the resulting respiratory disease, characterized by airway obstruction due to the presence of a thick mucus that is difficult to clear from airway surfaces. This thickened airway liquid contributes to recurrent bacterial infections and progressively impaired respiration, eventually resulting in death.
In cystic fibrosis, defective chloride transport is generally due to a mutation in a chloride channel known as the cystic fibrosis transmembrane conductance regulator (CFTR; see Riordan et al., Science 245:1066-73, 1989). CFTR is a linear chloride channel found in the plasma membrane of certain epithelial cells, where it regulates the flow of chloride ions in response to phosphorylation by a cyclic AMP-dependent kinase. Many mutations of CFTR have been reported, the most common of which is a deletion of phenylalanine at position 508 (ΔF508-CFTR), which is present in approximately 70% of patients with cystic fibrosis. A glycine to aspartate substitution at position 551 (G551D-CFTR) occurs in approximately 1% of cystic fibrosis patients.
Current treatments for cystic fibrosis generally focus on controlling infection through antibiotic therapy and promoting mucus clearance by use of postural drainage and chest percussion. However, even with such treatments, frequent hospitalization is often required as the disease progresses. New therapies designed to increase chloride ion conductance in airway epithelial cells have been proposed, but their long term beneficial effects have not been established and such therapies are not presently available to patients.
Accordingly, improvements are needed in the treatment of cystic fibrosis. The present invention fulfills this need and further provides other related advantages.
Briefly stated, the present invention provides compositions and methods for enhancing chloride transport in epithelial cells and for the therapy of cystic fibrosis. Within one aspect, the present invention provides methods for enhancing chloride transport in epithelial cells, comprising contacting epithelial cells with a compound selected from the group consisting of flavones and isoflavones, wherein the compound is capable of stimulating chloride transport and wherein the compound is not genistein. Within certain embodiments, the compound is (a) a polyphenolic compound having the general formula: ##STR1##
wherein carbon atoms at positions 2, 3, 5, 6, 7, 8, 2', 3', 4', 5' and 6' are bonded to a moiety independently selected from the group consisting of hydrogen atoms, hydroxyl groups and methoxyl groups, and wherein X is a single bond or a double bond; or (b) a stereoisomer or glycoside derivative of any of the foregoing polyphenolic compounds. Such compounds include, within certain embodiments, quercetin, apigenin, kaempferol, biochanin A, flavanone, flavone, dihydroxyflavone, trimethoxy-apigenin, apigenin 7-O-neohesperidoside, fisetin, rutin, daidzein and prunetin. For enhancing chloride transport in airway epithelial cells of a mammal, compounds may be administered orally or by inhalation. Other epithelial cells that may be employed include intestinal, pancreas, gallbladder, sweat duct, salivary gland and mammary epithelial cells. Within certain embodiments, the compound is combined with a substance that increases expression of a CFTR; and/or a chemical chaperone that increases trafficking of a CFTR to the plasma membrane.
Within other aspects, methods for enhancing chloride transport in epithelial cells may comprise contacting epithelial cells with a compound selected from the group consisting of reservatrol, ascorbic acid, ascorbate salts and dehydroascorbic acid. Such compounds may further be used in combination with a flavone or isoflavone as provided above.
Within other aspects, the present invention provides methods for treating cystic fibrosis in a patient, comprising administering to a patient a compound as described above, wherein the compound is capable of stimulating chloride transport. Within certain embodiments, the compound is genistein, quercetin, apigenin, kaempferol, biochanin A, flavanone, flavone, dihydroxyflavone, trimethoxy-apigenin, apigenin 7-O-neohesperidoside, fisetin, rutin, daidzein or prunetin. Within other embodiments, the compound is reservatrol, ascorbic acid, ascorbate salts and dehydroascorbic acid. Such compounds may be administered alone or in combination. Compounds may be administered orally or by inhalation. Within certain embodiments, the compound is combined with a substance that increases expression of a CFTR; and/or a chemical chaperone that increases trafficking of a CFTR to the plasma membrane.
Within further related aspects, the present invention provides methods for increasing chloride ion conductance in airway epithelial cells of a patient afflicted with cystic fibrosis, wherein the patient's CFTR protein has a deletion at position 508, the method comprising administering to a mammal one or more compounds as described above, wherein the compound is capable of stimulating chloride secretion in the airway epithelial cells.
Within still further related aspects, the present invention provides methods for increasing chloride ion conductance in airway epithelial cells of a patient afflicted with cystic fibrosis, wherein the patient's CFTR protein has a mutation at position 551, the method comprising administering to a mammal one or more compounds as described above, wherein the compound is capable of stimulating chloride secretion in the airway epithelial cells.
Within further aspects, pharmaceutical compositions for treatment of cystic fibrosis are provided, comprising (a) one or more flavones or isoflavones capable of stimulating chloride transport and (b) one or more of: (i) a compound that increases expression of a CFTR in an epithelial cell; and/or (ii) a chemical chaperone that increases trafficking of a CFTR to a plasma membrane in an epithelial cell; and; and in combination with a pharmaceutically acceptable carrier. Within certain embodiments, the flavone or isoflavone may be genistein, quercetin, apigenin, kaempferol, biochanin A, flavanone, flavone, dihydroxyflavone, trimethoxy-apigenin, apigenin 7-O-neohesperidoside, fisetin, rutin, daidzein and/or prunetin, in combination with a pharmaceutically acceptable carrier.
Within still further aspects, a pharmaceutical composition for treatment of cystic fibrosis may comprise: (a) a polyphenolic compound having the general formula: ##STR2##
wherein carbon atoms at positions 2, 3, 5, 6, 7, 8, 2', 3', 4', 5' and 6' are bonded to a moiety independently selected from the group consisting of hydrogen atoms, hydroxyl groups and methoxyl groups, and wherein X is a single bond or a double bond; or a stereoisomer or glycoside derivative of any of the foregoing polyphenolic compounds; (b) a compound selected from the group consisting of reservatrol, ascorbic acid, ascorbate salts and dehydroascorbic acid; and (c) a physiologically acceptable carrier.
These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.
FIG. 1 is a recording of transepithelial short-circuit current (Y axis) as a function of time (X axis), showing the effect of apigenin on the current across a Calu-3 cell monolayer. Measurements were performed in an Ussing chamber, where the basolateral membrane was permeabilized with α-toxin and a chloride gradient was applied across the apical membrane as a driving force. Tissue was first stimulated with cAMP (100 μM). Apigenin (50 μM) was subsequently added as indicated. The horizontal bar represents 100 seconds, and the vertical bar represents 12 μA/cm2.
FIG. 2 is a recording showing the effect of quercetin on transepithelial short-circuit current across a Calu-3 cell monolayer in an Ussing chamber, where the basolateral membrane was permeabilized with α-toxin and a chloride gradient was applied across the apical membrane as a driving force. Tissue was first stimulated with cAMP (100 μM). Quercetin (30 μM) was subsequently added as indicated. Bars are 140 seconds (horizontal) and 12 μA/cm2 (vertical).
FIG. 3 is a recording illustrating the dose-dependent stimulation of transepithelial chloride secretion by quercetin (in the amounts indicated) across a primary bovine tracheal epithelium. Amiloride (50 μM) was added to block sodium transport as indicated. The CFTR channel blocker diphenylcarboxylate (DPC, 5 mM) was added as shown.
FIG. 4 is a recording showing the effect of biochanin A on transepithelial short-circuit current across a Calu-3 cell monolayer in an Ussing chamber, where the basolateral membrane was permeabilized with α-toxin and a chloride gradient was applied across the apical membrane as a driving force. The tissue was first stimulated with forskolin (Fsk, 10 μM). Subsequent addition of biochanin A (Bio, 100 and 300 μM) was subsequently added as indicated.
FIG. 5 is a cell-attached single channel patch clamp recording from a 3T3 cell expressing ΔF508-CFTR. The cell was treated with 10 μM forskolin as shown. Genistein (50 μM) and apigenin (50 μM), were added where indicated by boxes. The holding potential was 75 mV, and channel openings were upward.
FIG. 6 is a whole cell patch clamp recording on an airway epithelial cell homozygous for ΔF508-CFTR. Before the measurement, the cell was incubated for 2 days in 5 mM 4-phenylbutyrate. 30 μM quercetin was added where indicated by the box. Further stimulation by forskolin (10 μLM) is also shown. The holding potential was -60 mV.
FIG. 7 is a recording illustrating the effect of genistein on G551D-CFTR expressed in a Xenopus oocyte. Current was measured with the two-electrode voltage clamp technique. G551D-CFTR was injected in oocyte. Current was first stimulated with forskolin (10 μM) and isobutylmethylxantine (IBMX; 2 mM). Genistein (50 μM) was added as indicated. The right panel shows current voltage relations recorded after treatment with forskolin and IBMX (F/I) and after treatment with genistein (F/I+Geni). A voltage ramp from -130 mV to +70 mV was applied and current was recorded during the two conditions.
FIG. 8 is a recording illustrating the effect of quercetin on nasal potential difference (PD) measurement in a healthy human volunteer. Amiloride (50 μM) was added to block sodium transport as indicated. Conditions were rendered chloride free (Cl free) and chloride secretion was stimulated with isoproterenol (iso; 5 μM). Quercetin (querc; 10 μM) was added as indicated.
FIG. 9 is a recording illustrating the effect of apigenin and kaempferol on nasal PD in mice. Chloride secretion was stimulated with isoproterenol (iso; 5 μM), and amiloride (50 μM) was added to block sodium transport as indicated. Under chloride-free conditions (Cl free), apigenin (50 μM, left panel) and kaempferol (kaemp, 50 μM, right panel) were added as indicated.
FIG. 10 is a recording illustrating the effect of genistein, with and without 4-phenylbutyrate. on chloride current in JME cells. The recording was performed at 0 mV holding potential with a 17:150 mM chloride gradient from bath to pipette. The bottom trace is from an untreated cell and the top trace is from a cell that had been incubated in 5 mM 4-phenylbutyrate (4-PB) for two days. Forskolin (10 μM) and genistein (30 μM) were added as indicated.
FIGS. 11A-11C are a whole cell patch clamp recording (FIG. 11A) and graphs (FIGS. 11B and 11C) illustrating the effect of forskolin and genistein on HeLa cells infected with a G551D-CFTR-containing adenovirus. Cells were stimulated with forskolin (10 μM) and genistein (30 μM), as indicated. The fit of the data with the Goldman equation is shown by the line in FIG. 11B. A current variance to mean current plot is shown in FIG. 11C.
FIGS. 12A and 12B illustrate the use of representative flavenoids for the treatment of CF patients. FIG. 12A shows a recording from a patient with the genotype G551D/ΔF508. Amiloride, chloride free solution and isoproterenol were added as indicated. The addition of genistein, as indicated, hyperpolarized nasal PD. FIG. 12B is a graph illustrating the average responses of nasal PD to genistein and quercetin of four CF patients with the G551D mutation. The filled bars show, for comparison, the respective responses in healthy subjects.
FIGS. 13A-13C illustrate the effect of additional representative flavenoids and isoflavenoids on chloride current in epithelial cells. FIG. 13A is a graph showing the stimulation of transepithelial chloride currents by reservatrol (100 μM), flavanone (100 μM), flavone (200 μM), apigenin (20 μM), apigenin 7-O-neohesperidoside (30 μM), kaempferol (20 μM), fisetin (100 μM), quercetin (30 μM), rutin (30 μM), genistein (30 μM), daidzein (50 μM), biochanin A (100 μM) and prunetin (100 μM) in Calu-3 monolayers. Experiments were performed in the presence of 10 μM forskolin. Stimulated currents are plotted relative to forskolin stimulated increase (forskolin stimulated currents are 100%). FIG. 13B is a recording showing the effect of 7,4'-Dihydroxyflavone on chloride current in unstimulated tissue. This recording shows a dose-dependent stimulation of transepithelial short-circuit current (Isc) across Calu-3 monolayers by 7,4'-Dihydroxyflavone. Increasing concentrations of 7,4'-Dihydroxyflavone (as indicated in μM) were added to mucosal side and dose-dependently stimulated chloride currents. Currents were recorded with a serosal-to-mucosal chloride gradient at 0 mV and pulses were obtained at 2 mV. FIG. 13C is a recording illustrating the effect of trimethoxy-apigenin. This recording shows dose-dependent stimulation of transepithelial short-circuit current (Isc) across Calu-3 monolayers by trimethoxy-apigenin. Increasing concentrations of trimethoxy-apigenin (as indicated in μM) were added to mucosal side and dose-dependently stimulated chloride currents. Experiment was performed on unstimulated tissue. Currents were recorded with a serosal-to-mucosal chloride gradient at 0 mV and pulses were obtained at 2 mV.
FIG. 14 is a recording illustrating the dose-dependent stimulation of transepithelial short-circuit current (Isc) across Calu-3 monolayers by reservatrol. Increasing concentrations of reservatrol (as indicated in μM) were added to the mucosal perfusion and dose-dependently increased chloride currents. For comparison, currents were further stimulated by serosal addition of 20 μM forskolin. Stimulated chloride current was completely blocked by addition of the chloride channel blocker DPC (5 mM). Currents were recorded with a serosal-to-mucosal chloride gradient at 0 mV and pulses were obtained at 2 mV.
FIG. 15 is a recording showing L-ascorbic acid and genistein stimulation of transepithelial short-circuit current (Isc) across Calu-3 monolayers. Ascorbic acid (100 μM) was added as indicated. For comparison, ascorbic acid-stimulated chloride current was subsequently stimulated by the cAMP elevating agonist forskolin (20 μM, serosal). The CFTR activator genistein (20 mM) was then added to the mucosal perfusion as indicated. Stimulated current was completely blocked by addition of the chloride channel blocker DPC (5 mM), added as indicated. Currents were recorded with a serosal-to-mucosal chloride gradient at 0 mV and pulses were obtained at 2 mV.
FIG. 16 is a recording showing L-Ascorbic acid and kaempferol stimulation of transepithelial short-circuit current (Isc) across Calu-3 monolayers. 100 μM ascorbic acid and forskolin (fsk, 20 μM, serosal) were added as indicated. The CFTR activator kaempferol (20 μM) was subsequently added, as indicated. Stimulated current was completely blocked by addition of the chloride channel blocker DPC (5 mM). Currents were recorded with a serosal-to-mucosal chloride gradient at 0 mV and pulses were obtained at 2 mV.
FIG. 17 is a recording illustrating the effect of L-ascorbic acid on nasal potential difference in human subjects. Amiloride, chloride-free solution and L-ascorbic acid (100 μM) were added to the luminal perfusate in the nose. as indicated. The β-adrenergic agonist isoproterenol was also added as indicated. Stimulation was reversed by washing out drugs with NaCl Ringer solution.
FIG. 18 is a recording illustrating the stimulation of transepithelial short-circuit current (Isc) across Calu-3 monolayers by addition of 10, 100 and 300 μM dehydroascorbic acid. Currents were recorded with a serosal-to-mucosal chloride gradient at 0 mV and pulses were obtained at 2 mV.
FIG. 19 is a recording illustrating the stimulatory effect of 20 μM genistein on transepithelial short-circuit current (Isc) across 31EG4 mammary epithelial monolayers. Na currents were blocked by mucosal addition of amiloride (10 mM), and chloride currents were further stimulated by forskolin (20 μM, serosal), as indicated. Currents were recorded in symmetrical NaCl Ringers solution at 0 mV and pulses were obtained at 2 mV.
As noted above, the present invention is generally directed to compositions and methods for the treatment of diseases characterized by defective chloride transport in epithelial tissues, including cystic fibrosis, and diseases with excessive accumulation of mucus, including cystic fibrosis, chronic bronchitis and asthma. It has been found, within the context of the present invention, that certain flavones and isoflavones, as well as other polyphenolic compounds, are capable of stimulating CFTR-mediated chloride transport in epithelial tissues (e.g., tissues of the airways, intestine, pancreas and other exocrine glands) in a cyclic-AMP independent manner. Ascorbic acid and derivatives thereof may also, or alternatively, be used within such methods. It has further been found, within the context of the present invention, that such compounds stimulate chloride transport in cells with a mutated CFTR (e.g., ΔF508-CFTR or G551D-CFTR). Such therapeutic compounds may be administered to patients afflicted with cystic fibrosis as described herein.
The term "flavones," as used herein refers to a compound based on the core structure of flavone: ##STR3##
An "isoflavone" is an isomer of a flavone (i.e., the phenyl moiety at position 2 is moved to position 3), and having the core structure shown below: ##STR4##
Certain flavones and isoflavones have the structure: ##STR5##
wherein carbon atoms at positions 2, 3, 5, 6, 7, 8, 2', 3', 4', 5' and 6' are bonded to a moiety independently selected from the group consisting of hydrogen atoms, hydroxyl groups and methoxyl groups, and wherein X is a single bond or a double bond. Stereoisomers and glycoside derivatives of such polyphenolic compounds may also be used within the methods provided herein.
Many flavones are naturally-occurring compounds, but synthetic flavones and isoflavones are also encompassed by the present invention. A flavone or isoflavone may be modified to comprise any of a variety of functional groups, such as hydroxyl and/or ether groups. Preferred flavones comprise one or more hydroxyl groups, such as the trihydroxyflavone apigenin, the tetrahydroxyflavone kaempferol and the pentahydroxyflavone quercetin. Preferred isoflavones comprise one or more hydroxyl and/or methoxy groups, such as the methoxy, dihydroxy isoflavone biochanin A. Genistein is yet another preferred isoflavone for use within the methods provided herein.
Flavones and isoflavones for use within the context of the present invention have the ability to stimulate chloride transport in epithelial tissues. Such transport may result in secretion or absorption of chloride ions. The ability to stimulate chloride transport may be assessed using any of a variety of systems. For example, in vitro assays using a mammalian trachea or a cell line, such as the permanent airway cell line Calu-3 (ATCC Accession Number HTB55) may be employed. Alternatively, the ability to stimulate chloride transport may be evaluated within an in vivo assay employing a mammalian nasal epithelium. In general, the ability to stimulate chloride transport may be assessed by evaluating CFTR-mediated currents across a membrane by employing standard Ussing chamber (see Ussing and Zehrahn, Acta. Physiol. Scand. 23:110-127, 1951) or nasal potential difference measurements (see Knowles et al., Hum. Gene Therapy 6:445-455, 1995). Within such assays, a flavone or isoflavone that stimulates a statistically significant increase in chloride transport at a concentration of about 1-300 μM is said to stimulate chloride transport.
Within one in vitro assay, the level of chloride transport may be evaluated using mammalian pulmonary cell lines, such as Calu-3 cells, or primary bovine tracheal cultures. In general, such assays employ cell monolayers, which may be prepared by standard cell culture techniques. Within such systems, CFTR-mediated chloride current may be monitored in an Ussing chamber using intact epithelia. Alternatively, chloride transport may be evaluated using epithelial tissue in which the basolateral membrane is permeabilized with Staphylococcus aureus α-toxin, and in which a chloride gradient is imposed across the apical membrane (see Illek et al., Am. J. Physiol. 270:C265-75, 1996). In either system, chloride transport is evaluated in the presence and absence of a test compound (i.e., a flavone or isoflavone), and those compounds that stimulate chloride transport as described above may be used within the methods provided herein.
Within another in vitro assay for evaluating chloride transport, cells are transfected with a chloride channel gene (e.g., CFTR) having a mutation associated with cystic fibrosis. Any CFTR gene that is altered relative to the normal human sequence provided in SEQ ID NO: 1, such that the encoded protein contains a mutation associated with cystic fibrosis, may be employed within such an assay. The most common disease-causing mutation in cystic fibrosis is a deletion of phenylalanine at position 508 in the CFTR protein (ΔF508-CFTR; SEQ ID NO:4). Accordingly, the use of a CFTR gene encoding ΔF508-CFTR is preferred. However, genes encoding other altered CFTR proteins (e.g., G551D-CFTR; containing a glycine to aspartate point mutation at position 551; SEQ ID NO:6) may also be used. Cells such as NIH 3T3 fibroblasts may be transfected with an altered CTFR gene, such as ΔF508-CFTR, using well known techniques (see Anderson et al., Science 25:679-682, 1991). The effect of a compound on chloride transport in such cells may be evaluated by monitoring CFTR-mediated currents using the patch clamp method (see Hamill et al., Pflugers Arch. 391:85-100, 1981) with and without compound application.
Within another in vitro assay, a mutant CFTR may be microinjected into cells such as Xenopus oocytes. Chloride conductance mediated by the CFTR mutant in the presence and absence of a test compound may be monitored with the two electrode voltage clamp method (see Miledi et al., Proc. R. Soc. Lond. Biol. 218:481-484, 1983).
Alternatively, such assays may be performed using a mammalian trachea, such as a primary cow tracheal epithelium using the Ussing chamber technique as described above. Such assays are performed in the presence and absence of test compound to identify flavone and isoflavones that stimulate chloride transport.
Any of the above assays may be performed following pretreatment of the cells with a substance that increases the concentration of CFTR mutants in the plasma membrane. Such substances include chemical chaperones, which support correct trafficking of the mutant CFTR to the membrane, and compounds that increase expression of CFTR in the cell (e.g., transcriptional activators). A "chemical chaperone," as used herein is any molecule that increases trafficking of proteins to a cell membrane. More specifically, a chemical chaperone within the context of the present invention increases trafficking of a mutant CFTR (e.g., the Δ508-CFTR and/or G551D-CFTR) to the membrane by a statistically significant amount. Chemical chaperones for use herein include, but are not limited to, glycerol, dimethylsulfoxide, trimethylamine N-oxide, taurin, methylamine and deoxyspergualin (see Brown et al., Cell Stress Chaperones 1:117-125, 1996; Jiang et al., Amer. J. Physiol.-Cell Physiol. 44:C171-C178, 1998). Compounds that increase expression of CFTR in the cell include 4-phenylbutyrate (Rubenstein et al., J. Clin. Invest. 100:2457-2465, 1997) and sodium butyrate (Cheng et al., Am. J. Physiol. 268:L615-624, 1995). Other compounds that increase the level of CFTR in the plasma membrane (by increasing correct trafficking and/or expression of the CFTR) may be readily identified using well known techniques, such as immunohistochemical techniques, to evaluate effects on levels of plasma membrane CFTR.
In vivo, chloride secretion may be assessed using measurements of nasal potential differences in a mammal, such as a human or a mouse. Such measurements may be performed on the inferior surface of the inferior turbinate following treatment of the mucosal surface with a test compound during perfusion with the sodium transport blocker amiloride in chloride-free solution. The nasal potential difference is measured as the electrical potential measured on the nasal mucosa with respect to a skin electrode placed on a slightly scratched skin part (see Alton et al., Eur. Respir. J. 3:922-926, 1990) or with respect to a subcutaneous needle (see Knowles et al., Hum. Gene Therapy 6:445-455, 1995). Nasal potential difference is evaluated in the presence and absence of test compound, and those compounds that results in a statistically significant increase in nasal potential difference stimulate chloride transport.
Compounds as provided herein may generally be used to chloride transport within any of a variety of CFTR-expressing epithelial cells. CFTR is expressed in may epithelial cells, including intestinal, airway, pancreas, gallbladder, sweat duct, salivary gland and mammary epithelia. All such CFTR-expressing organs are subject to stimulation my the compounds provided herein.
As noted above, any flavone or isoflavone that stimulates chloride transport within at least one of the above assays may be used for therapy of cystic fibrosis, other diseases characterized by abnormally high mucus accumulation in the airways or intestinal disorders such as constipation. Preferred therapeutic compounds include flavones and isoflavones that occur naturally in plants and are part of the human diet. Preferred compounds include genistein (4',5,7-trihydroxyisoflavone), as well as quercetin (3,3',4',5,7-pentahydroxyflavone), apigenin (4'5,7-trihydroxyflavone), kaempferol (3,4',5,7-tetrahydroxyflavone) and biochanin A (4'-methoxy-5,7-dihydroxyisoflavone), as depicted below: ##STR6##
Other suitable therapeutic compounds may be identified using the resentative assays as described herein. Additional representative flavones and flavones include flavanone, flavone, dihydroxyflavone, trimethoxy-apigenin, genin 7-O-neohesperidoside, fisetin, rutin, daidzein and prunetin. Representative vones and isoflavones are summarized in Tables I and II.
| TABLE I |
| Flavonoids |
| No. Name X C3 C5 C7 C3' C4' |
| 1 Apigenin ═ OH OH OH |
| 2 Apigenin7-O- ═ OH ONeo OH |
| neohesperidoside |
| 3 Dihydroxyflavone ═ OH OH |
| 4 Flavone ═ |
| 5 Flavanone -- |
| 6 Fisetin ═ OH OH OH OH |
| 7 Kaempferol ═ OH OH OH OH |
| 8 Quercetin ═ OH OH OH OH OH |
| 9 Rutin ═ ORut OH OH OH |
| 10 Trimethoxy- ═ H OCH3 OCH3 OCH3 |
| apigenin |
| where ═ a double bond, |
| -- is a single bond, |
| ONeo is Neohesperidoside, |
| ORut is rutinoside, |
| OCH3 is methoxy, |
| OH is hydroxy |
| TABLE II |
| Isoflavonoids |
| No. Name X C5 C7 C4' |
| 11 Biochanin ═ OH OH OCH3 |
| 12 Daidzein ═ OH OH |
| 13 Genistein ═ OH OH OH |
| 14 Prunetin ═ OH OCH3 OH |
| where ═ a double bond, -- is a single bond, ONeo is Neohesperidoside, |
| ORut is rutinoside, OCH3 is methoxy, OH is hydroxy. |
Genistein, quercetin, apigenin, kaempferol, biochanin A and other flavones and isoflavones may generally be prepared using well known techniques, such as those described by Shakhova et al., Zh. Obshch. Khim. 32:390, 1962; Farooq et al., Arch. Pharm. 292:792, 1959; and Ichikawa et al., Org. Prep. Prog. Int. 14:183, 1981. Alternatively, such compounds may be commercially available (e.g, from Indofine Chemical Co., Inc., Somerville, N.J. or Sigma-Aldrich, St. Louis, Mo.). Further modifications to such compounds may be made using conventional organic chemistry techniques, which are well known to those of ordinary skill in the art.
As noted above, other polyphenolic compounds may be used within the methods provided herein. For example, trihydroxystilbenes such as reservatrol (trans-3,5,4'-trihydroxystilbene) may be employed. Reservatrol is a polyphenolic compound having the following structure: ##STR7##
Other compounds that may be used within the methods provided herein are ascorbic acid and derivatives thereof. Such compounds include L-ascorbic acid (L-xyloascorbic acid), dehydrascorbic acid (L-thero-2,3-Hexodiulosoinic acid γ-lactone) and salts foregoing acids. ##STR8##
Within certain preferred embodiments, ascorbic acid or a derivative thereof is used in combination with a polyphenolic compound as described above. Certain representative combinations include ascorbic acid and one or more flavenoids and/or isoflavenoids (such as genistein and ascorbic acid; and kaempferol and ascorbic acid). Ascorbic acid may generally be used to treat or prevent genetic loss of chloride secretory function (e.g. cystic fibrosis), as well as other related loss or reduced chloride secretory function (e.g., intestinal constipation, dry eye syndrome and obstructive airway diseases).
For in vivo use, a therapeutic compound as described herein is generally incorporated into a pharmaceutical composition prior to administration. Within such compositions, one or more therapeutic compounds as described herein are present as active ingredient(s) (i.e., are present at levels sufficient to provide a statistically significant effect on nasal potential difference, as measured using a representative assay as provided herein). A pharmaceutical composition comprises one or more such compounds in combination with any physiologically acceptable carrier(s) and/or excipient(s) known to those skilled in the art to be suitable for the particular mode of administration. In addition, other pharmaceutically active ingredients (including other therapeutic agents) may, but need not, be present within the composition.
Within certain methods provided herein, a flavone or isoflavone may be combined with a substance that increases the concentration of CFTR mutants in the plasma membrane of a cell. As noted above, such substances include chemical chaperones, which support correct trafficking of the mutant CFTR to the membrane, and compounds that increase expression of CFTR in the membrane. These substances may be contained within the same pharmaceutical composition or may be administered separately. Preferred chemical chaperones include glycerol, dimethylsulfoxide, trimethylamine N-oxide, taurin, methylamine and deoxyspergualin, and compounds that increase expression of CFTR in the membrane include 4-phenylbutyrate and sodium butyrate. The use of flavenoid and/or isoflavenoid compounds, as described herein, in combination with such substances may increase mutant CFTR activity, and ameliorate symptoms of cystic fibrosis.
Administration may be achieved by a variety of different routes. One preferred route is oral administration of a composition such as a pill, capsule or suspension. Such compositions may be prepared according to any method known in the art, and may comprise any of a variety of inactive ingredients. Suitable excipients for use within such compositions include inert diluents (which may be solid materials, aqueous solutions and/or oils) such as calcium or sodium carbonate, lactose, calcium or sodium phosphate, water, arachis oil, peanut oil liquid paraffin or olive oil; granulating and disintegrating agents such as maize starch, gelatin or acacia and/or lubricating agents such as magnesium stearate, stearic acid or talc. Other inactive ingredients that may, but need not, be present include one or more suspending agents (e.g., sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia), thickeners (e.g., beeswax, paraffin or cetyl alcohol), dispersing or wetting agents, preservatives (e.g., antioxidants such as ascorbic acid), coloring agents, sweetening agents and/or flavoring agents.
A pharmaceutical composition may be prepared with carriers that protect active ingredients against rapid elimination from the body, such as time release formulations or coatings. Such carriers include controlled release formulations, such as, but not limited to, microencapsulated delivery systems, and biodegradable, biocompatible polymers, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid and others known to those of ordinary skill in the art.
Particularly preferred are methods in which the therapeutic compound(s) are directly administered as a pressurized aerosol or nebulized formulation to the patient's lungs via inhalation. Such formulations may contain any of a variety of known aerosol propellants useful for endopulmonary and/or intranasal inhalation administration. In addition, water may be present, with or without any of a variety of cosolvents, surfactants, stabilizers (e.g., antioxidants, chelating agents, inert gases and buffers). For compositions to be administered from multiple dose containers, antimicrobial agents are typically added. Such compositions are also generally filtered and sterilized, and may be lyophilized to provide enhanced stability and to improve solubility.
Pharmaceutical compositions are administered in an amount, and with a frequency, that is effective to inhibit or alleviate the symptoms of cystic fibrosis and/or to delay the progression of the disease. The effect of a treatment may be clinically determined by nasal potential difference measurements as described herein. The precise dosage and duration of treatment may be determined empirically using known testing protocols or by testing the compositions in model systems known in the art and extrapolating therefrom. Dosages may also vary with the severity of the disease. A pharmaceutical composition is generally formulated and administered to exert a therapeutically useful effect while minimizing undesirable side effects. In general, an oral dose ranges from about 200 mg to about 1000 mg, which may be administered 1 to 3 times per day. Compositions administered as an aerosol are generally designed to provide a final concentration of about 10 to 50 μM at the airway surface, and may be administered 1 to 3 times per day. It will be apparent that, for any particular subject, specific dosage regimens may be adjusted over time according to the individual need.
As noted above, a pharmaceutical composition may be administered to a mammal to stimulate chloride transport, and to treat cystic fibrosis. Patients that may benefit from administration of a therapeutic compound as described herein are those afflicted with cystic fibrosis. Such patients may be identified based on standard criteria that are well known in the art, including the presence of abnormally high salt concentrations in the sweat test, the presence of high nasal potentials, or the presence of a cystic fibrosis-associated mutation. Activation of chloride transport may also be beneficial in other diseases that show abnormally high mucus accumulation in the airways, such as asthma and chronic bronchitis. Similarly, intestinal constipation may benefit from activation of chloride transport by a flavone or isoflavone as provided herein.
SEQ ID NO:1 is a DNA sequence encoding human CFTR.
SEQ ID NO:2 is an amino acid sequence of human CFTR.
SEQ ID NO:3 is a DNA sequence encoding human CFTR with the ΔF508 mutation.
SEQ ID NO:4 is an amino acid sequence of human CFTR with the ΔF508 mutation.
SEQ ID NO:5 is a DNA sequence encoding human CFTR with the G551D mutation.
SEQ ID NO:6 is an amino acid sequence of human CFTR with the G551D mutation.
The following Examples are offered by way of illustration and not by way of limitation.
PAC Example 1This Example illustrates the use of the representative compounds apigenin, quercetin and biochanin A to enhance chloride secretion in Calu-3 human pulmonary cultures or in primary bovine tracheal cultures.
A Calu-3 cell monolayer was prepared in an Ussing chamber as described by Illek et al., Am. J. Physiol. 270:C265-275, 1996. The basolateral membrane was permeabilized with α-toxin and a chloride gradient was applied across the apical membrane as a driving force (see Illek et al, Am. J. Physiol. 270:C265-C275, 1996). The tissue was first stimulated with cAMP (100 μM), and then with a representative flavone or isoflavone.
As shown in FIGS. 1 and 2, subsequent addition of apigenin or quercetin further stimulated chloride current. FIG. 1 illustrates the short circuit current across the Calu-3 cell monolayer before and after addition of apigenin (50 μM). FIG. 2 illustrates the effect of quercetin (30 μM) on chloride current across a Calu-3 monolayer. In both cases, the flavone stimulated chloride current beyond the stimulation achieved by cAMP.
FIG. 3 illustrates the results of a related experiment to evaluate the dose-dependent stimulation of transepithelial chloride secretion by quercetin across a primary bovine tracheal epithelium. The epithelial cells were first treated with amiloride (50 μM), and then with quercetin at the indicated concentrations. The dose-response relation yielded a half maximal stimulation at 12.5 μM. At high concentrations of quercetin, the current was blocked. Current was fully inhibited by the CFTR channel blocker diphenylcarboxylate (DPC, 5 mM).
To evaluate the effect of biochanin A, a Calu-3 cell monolayer was prepared and permeabilized as described above. The tissue was first stimulated with forskolin (Fsk, 10 μM). The effect of biochanin A (Bio, 100 and 300 μM) on short-circuit current (Isc) across the Calu-3 monolayer was evaluated in an Ussing chamber. As shown in FIG. 4, biochanin A further stimulated chloride secretion.
PAC Activation of Mutant CFTR by Representative Flavones and IsoflavonesThis Example illustrates the use of the representative compounds apigenin, quercetin and genistein to activate ΔF508-CFTR and G551D-CFTR in different cell types.
A cell-attached single channel patch clamp recording was obtained from a 3T3 cell expressing ΔF508-CFTR as described by Hamill et al., Pflugers Arch. 391:85-100, 1981 and Fischer and Machen, J. Gen. Physiol. 104:541-566, 1994. As shown in FIG. 5, stimulation of the cell with 10 μM forskolin did not activate ΔF508-CFTR channel, but addition of genistein (50 μM) or apigenin (50 μM, where indicated by boxes) induced ΔF508-CFTR channel openings, and removal of these compounds inactivated the channels. The holding potential was 75 mV, and channel openings were upward.
FIG. 6 presents a whole cell patch clamp recording on an airway epithelial cell homozygous for ΔF508-CFTR (cell type: JME cell, see Jeffersen et al., Am. J. Physiol. 259:L496-L505, 1990). Before the measurement, the cell was incubated for 2 days in 5 mM 4-phenylbutyrate to enhance ΔF508-CFTR expression in the plasma membrane (Rubenstein & Zeitlin, Ped. Pulm. Suppl. 12:234, 1995). Measurements were performed as described by Fischer et al., J. Physiol. Lond. 489:745-754, 1995. Addition of 30 μM quercetin activated chloride current in the whole cell mode, which was further stimulated by forskolin. The holding potential was -60 mV.
The effect of genistein on chloride current in a Xenopus oocyte expressing G551D-CFTR was measured with the two-electrode voltage clamp technique (see Miledi et al., Proc. R. Soc. Lond. Biol. 218:481-484, 1983). G551D-CFTR (2 ng in 50 nL of water) was injected into the oocyte. Current was first stimulated with forskolin (10 μM) and isobutylmethylxantine (IBMX; 2 mM). Genistein (50 μM) was found to further activate chloride currents. As shown in FIG. 7, genistein increased conductance and shifted reversal potential to the right, which is indicative of a stimulated chloride current.
PAC Effect of Representative Flavones on Nasal Potential DifferenceThis Example illustrates the in vivo use of quercetin, apigenin and kaempferol to activate the nasal potential difference in humans and mice.
The effect of quercetin on nasal potential difference (PD) measurement in a healthy human volunteer was measured as described by Knowles et al., Hum. Gene Therapy 6:445-455, 1995. Under conditions where sodium transport was blocked with amiloride (50 μM) and chloride secretion was stimulated under chloride-free conditions with isoproterenol (5 μM), quercetin (10 μM) stimulated nasal PD further (FIG. 8).
The effect of apigenin and kaempferol on nasal PD in mice was evaluated using a method similar to that employed for measurements in humans, except that a plastic tube of approximately 0.1 mm diameter was used as an exploring nasal electrode. The plastic tube was perfused with test solutions at approximately 10 μL/min. After blocking sodium transport with amiloride (50 μM) and during stimulation of chloride secretion with isoproterenol (iso;5 μM) under chloride-free conditions, apigenin (50 μM, left panel) and kaempferol (kaemp, 50 μM, right panel) further stimulated nasal PD.
These results show that the representative flavenoids quercetin, apigenin, kaempferol and biochanin A stimulate chloride transport across epithelial tissues derived from the airways in vitro, and across nasal epithelium in vivo. The results also show that the CFTR mutants ΔF508 and G551D can be activated by the representative compounds genistein and apigenin.
PAC Effect of Genistein on Chloride Current in Cells Expressing a Mutant CFTRThis Example illustrates the ability of the representative isoflavone genistein to activate chloride current in cells expressing a mutant CFTR.
In one experiment, genistein was used in combination with 4-phenylbutyrate. Chloride current was measured in JME cells (human nasal epithelial cell line homozygous for the Δ508 mutation of CFTR; see Jefferson et al., Am. J. Physiol. 259:L496-505, 1990). The recording was performed at 0 mV holding potential with a 17:150 mM chloride gradient from bath to pipette. Under these conditions, the recorded current, shown in FIG. 10, is chloride current (Illek and Fischer, Am. J. Physiol. (Lung Cell. Mol. Physiol.):L902-910, 1998). The bottom trace in FIG. 10 is from an untreated cell. Neither forskolin (10 μM nor genistein (30 μM activated current. The top tracing in FIG. 10 is from a cell that had been incubated in 5 mM 4-phenylbutyrate (4-PB) for two days (Rubenstein et al., J. Clin. Invest. 100:2457-2465, 1997). After 4-PB treatment, chloride current was stimulated by forskolin (by on average 30.3±19.4 pS/pF, n=6), and further activated by genistein (to an average 105±84 pS/pF) in a CF cell with the Δ508-CFTR mutation. These results further demonstrate the ability of a flavenoid compound to optimize chloride currents elicited in CF cells by other means.
Within another experiment, HeLa cells infected with the G551D-CFTR-containing adenovirus were investigated in the patch clamp mode. Stimulation of the cell with forskolin (10 μM) stimulated only a very small current (FIGS. 11A and 11B). On average, forskolin-stimulated conductance was 9.5±5 pS/pF (n=4). Additional stimulation with genistein (30 μM) stimulated significant chloride currents, which were time- and voltage-independent (FIG. 11B) and well fitted with the Goldman equation (line in FIG. 11B; Illek and Fischer, Am. J. Physiol. (Lung Cell. Mol. Physiol.):L902-910, 1998), which are characteristics of CFTR-mediated currents. Average forskolin+genistein-activated conductance was 120±30 pS/pF (n=4). Current variance to mean current plot (FIG. 11C) were used to calculate the average open probability (Po shown on top of axis) of the population of channels carrying the total current (as described in Illek and Fischer, Am. J. Physiol. (Lung Cell. Mol. Physiol.):L902-910, 1998). During forskolin stimulation, maximal Po reached was 0.04 (open circles) and after additional stimulation with genistein Po reached a maximum of 0.42 in this recording. On average, after forskolin stimulation, Po =0.05±0.02 and after forskolin+genistein stimulation Po =0.54±0.12. For comparison, wild type CFTR expressed in HeLa cells and recorded under the same conditions resulted in Po =0.36±0.05 (n=3) after forskolin stimulation and Po =0.63±0.16 after forskolin+genistein treatment.
Effect of Representative Flavones on Nasal Potential Difference in CF Patients
This Example illustrates the in vivo use of quercetin and genistein to activate the nasal potential difference in CF patients bearing the G551D mutation.
Measurements were performed on patients as described by Alton et al., Eur. Respir. J. 3:922-926, 1990; Illek and Fischer, Am. J. Physiol. (Lung Cell. Mol. Physiol.):L902-910, 1998; and Knowles et al., Hum. Gene Therapy 6:445-455, 1995). The results are presented in FIGS. 12A and 12B. FIG. 12A shows a recording from a patient with the genotype G551D/ΔF508. Initial treatment with amiloride and chloride free solution had the purpose to isolate and amplify the chloride selective potentials. Addition of the beta-adrenergic agonist isoproterenol showed no effect, which is typical for CF patients (Knowles et al., Hum. Gene Therapy 6:445-455, 1995). However, addition of genistein hyperpolarized nasal PD. Average responses of nasal PD to genistein and quercetin of four CF patients with the G551D mutation are shown in FIG. 12B (open bars). The filled bars show for comparison the respective responses in healthy subjects. The genotypes of the 4 CF patients were: two G551D/ΔF508, one G551D/G551D and one G551D/unknown. Responses are most likely due to the G551D mutation because the homozygous G551D patient responded not different compared to the heterozygous G551D patients. Genistein and quercetin responses of nasal PD in CF patients were significant (p<0.05).
These results demonstrate that CFTR mutations are sensitive to flavenoid treatment, and provide additional evidence for therapeutic benefit of such compounds for the treatment of cystic fibrosis.
PAC Effect of Additional Representative Polyphenolic Compounds on Epithelial Cell Chloride CurrentsThis Example illustrates the effect of further flavenoids and isoflavenoids on chloride currents in airway epithelial cells.
Airway epithelial cells were prestimulated with 10 μM forskolin. The percent increase in chloride current was then determined following treatment with a series of polyphenolic compounds. FIG. 13A summarizes the stimulatory effect of these compounds. On average, chloride currents were further stimulated by reservatrol (100 μM) to 135%, by flavanone (100 μM) to 140%, by flavone (200 μM) to 128%, by apigenin (20 μM) to 241%, by apigenin 7-O-neohesperidoside (30 μM) to 155%, by kaempferol (20 μM) to 182%, by fisetin (100 μM) to 108%, by quercetin (30 μM) to 169%, by rutin (30 μM) to 149%, by genistein (30 μM) to 229%, by daidzein (50 μM) to 162%, by biochanin A (100 μM) to 139% and by prunetin (100 μM) to 161%.
The stimulatory effect of 7,4' Dihydroxyflavone is shown in FIG. 13B. Addition of 7,4'-Dihydroxyflavone to the mucosal perfusion dose-dependently stimulated transepithelial Cl currents in unstimulated Calu-3 monolayers. This experiment was performed using unstimulated tissue.
The stimulatory effect of trimethoxy-apigenin is shown in FIG. 13C. Addition of trimethoxy-apigenin to the mucosal perfusion dose-dependently stimulated transepithelial Cl currents in unstimulated Calu-3 monolayers. Kinetic analysis is depicted on the right panel and estimated half maximal stimulatory dose was 11.7 μM.
These results indicate that a variety of polyphenolic compounds stimulate chloride currents in epithelial cells.
PAC Effect of Reservatrol on Chloride CurrentsThis Example illustrates the stimulatory effect of reservatrol on transepithelial chloride currents.
Unstimulated Calu-3 monolayers were treated with increasing concentrations of reservatrol. FIG. 14 shows the recording generated following the addition of reservatrol to the mucosal perfusion dose-dependently stimulated transepithelial chloride currents in unstimulated Calu-3 monolayers. For comparison, currents were further stimulated by serosal addition of forskolin. The stimulated chloride current was completely blocked by the Cl channel blocker DPC. These results indicate that reservatrol stimulates transepithelial chloride transport.
PAC Effect of Ascorbic Acid and Dehydroascorbic Acid on Chloride CurrentsThis Example illustrates the stimulatory effect of ascorbic acid and dehydroascorbic acid on transepithelial chloride current.
Unstimulated Calu-3 monolayers were stimulated with L-ascorbic acid, as shown in FIG. 15. Addition of L-ascorbic acid to the mucosal or serosal perfusion very effectively stimulated transepithelial chloride secretion in unstimulated Calu-3 monolayers. For comparison, chloride currents were further stimulated by serosal addition of forskolin. In the continued presence of L-ascorbic acid and forskolin, it is remarkable that addition of genistein further stimulated chloride currents. These results indicate that genistein serves as a potent drug that is able to hyperstimulate chloride secretion and thereby maximize chloride transport across epithelia. The stimulated chloride current was completely blocked by the chloride channel blocker DPC.
The stimulatory effect of L-ascorbic acid is also shown in FIG. 16. Addition of 100 μM L-ascorbic acid to the mucosal or serosal perfusion very effectively stimulated transepithelial chloride currents in unstimulated Calu-3 monolayers. For comparison, ascorbic acid-stimulated chloride currents were stimulated by the cAMP elevating agonist forskolin (20 μM, serosal). Under these stimulated conditions kaempferol further hyperstimulated chloride currents. The stimulated chloride current was completely blocked by the chloride channel blocker DPC (5 mM).
The stimulatory effect of dehydroascorbic acid is shown in FIG. 18. Addition of dehydroascorbic acid at 10, 100 or 300 μM to the mucosal and serosal perfusion effectively stimulated transepithelial chloride currents in unstimulated Calu-3 monolayers. Stimulated Cl currents returned to baseline after 5-15 min.
PAC Effect of Ascorbic Acid on Chloride Currents in vivoThis Example illustrates the stimulatory effect of ascorbic acid on human nasal potential difference.
Nasal potential difference measurement was performed on a human volunteer according to a protocol by Knowles et al., Hum. Gene Therapy 6:445-455, 1995. Addition of L-ascorbic acid (100 μM) to the luminal perfusate in the nose (in the presence of amiloride (blocks Na currents) and in chloride-free solution) hyperpolarized nasal potential difference (PD) by 6.3 mV (FIG. 17). Addition of the β-adrenergic agonist isoproterenol further hyperpolarized nasal PD. Stimulation was reversed by washing out drugs with NaCl Ringer solution. These results demonstrate the ability of ascorbic acid to stimulate chloride transport in epithelia in humans.
PAC Effect of Genistein on Chloride Currents in Mammary EpitheliaThis Example illustrates the stimulatory effect of genistein in mammary epithelial cells.
The stimulation of transepithelial short-circuit current (Isc) across 31EG4 mammary epithelial monolayers by addition of 20 μM genistein is shown in FIG. 19. Na currents were blocked by mucosal addition of amiloride (10 mM). Chloride currents were further stimulated by forskolin (20 μM, serosal). Currents were recorded in symmetrical NaCl Ringers solution at 0 mV and pulses were obtained at 2 mV.
From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
| SEQUENCE LISTING |
| <100> GENERAL INFORMATION: |
| <160> NUMBER OF SEQ ID NOS: 6 |
| <200> SEQUENCE CHARACTERISTICS: |
| <210> SEQ ID NO 1 |
| <211> LENGTH: 6129 |
| <212> TYPE: DNA |
| <213> ORGANISM: Homo sapiens |
| <400> SEQUENCE: 1 |
| aattggaagc aaatgacatc acagcaggtc agagaaaaag ggttgagcgg caggcaccca 60 |
| gagtagtagg tctttggcat taggagcttg agcccagacg gccctagcag ggaccccagc 120 |
| gcccgagaga ccatgcagag gtcgcctctg gaaaaggcca gcgttgtctc caaacttttt 180 |
| ttcagctgga ccagaccaat tttgaggaaa ggatacagac agcgcctgga attgtcagac 240 |
| atataccaaa tcccttctgt tgattctgct gacaatctat ctgaaaaatt ggaaagagaa 300 |
| tgggatagag agctggcttc aaagaaaaat cctaaactca ttaatgccct tcggcgatgt 360 |
| tttttctgga gatttatgtt ctatggaatc tttttatatt taggggaagt caccaaagca 420 |
| gtacagcctc tcttactggg aagaatcata gcttcctatg acccggataa caaggaggaa 480 |
| cgctctatcg cgatttatct aggcataggc ttatgccttc tctttattgt gaggacactg 540 |
| ctcctacacc cagccatttt tggccttcat cacattggaa tgcagatgag aatagctatg 600 |
| tttagtttga tttataagaa gactttaaag ctgtcaagcc gtgttctaga taaaataagt 660 |
| attggacaac ttgttagtct cctttccaac aacctgaaca aatttgatga aggacttgca 720 |
| ttggcacatt tcgtgtggat cgctcctttg caagtggcac tcctcatggg gctaatctgg 780 |
| gagttgttac aggcgtctgc cttctgtgga cttggtttcc tgatagtcct tgcccttttt 840 |
| caggctgggc tagggagaat gatgatgaag tacagagatc agagagctgg gaagatcagt 900 |
| gaaagacttg tgattacctc agaaatgatt gaaaatatcc aatctgttaa ggcatactgc 960 |
| tgggaagaag caatggaaaa aatgattgaa aacttaagac aaacagaact gaaactgact 1020 |
| cggaaggcag cctatgtgag atacttcaat agctcagcct tcttcttctc agggttcttt 1080 |
| gtggtgtttt tatctgtgct tccctatgca ctaatcaaag gaatcatcct ccggaaaata 1140 |
| ttcaccacca tctcattctg cattgttctg cgcatggcgg tcactcggca atttccctgg 1200 |
| gctgtacaaa catggtatga ctctcttgga gcaataaaca aaatacagga tttcttacaa 1260 |
| aagcaagaat ataagacatt ggaatataac ttaacgacta cagaagtagt gatggagaat 1320 |
| gtaacagcct tctgggagga gggatttggg gaattatttg agaaagcaaa acaaaacaat 1380 |
| aacaatagaa aaacttctaa tggtgatgac agcctcttct tcagtaattt ctcacttctt 1440 |
| ggtactcctg tcctgaaaga tattaatttc aagatagaaa gaggacagtt gttggcggtt 1500 |
| gctggatcca ctggagcagg caagacttca cttctaatga tgattatggg agaactggag 1560 |
| ccttcagagg gtaaaattaa gcacagtgga agaatttcat tctgttctca gttttcctgg 1620 |
| attatgcctg gcaccattaa agaaaatatc atctttggtg tttcctatga tgaatataga 1680 |
| tacagaagcg tcatcaaagc atgccaacta gaagaggaca tctccaagtt tgcagagaaa 1740 |
| gacaatatag ttcttggaga aggtggaatc acactgagtg gaggtcaacg agcaagaatt 1800 |
| tctttagcaa gagcagtata caaagatgct gatttgtatt tattagactc tccttttgga 1860 |
| tacctagatg ttttaacaga aaaagaaata tttgaaagct gtgtctgtaa actgatggct 1920 |
| aacaaaacta ggattttggt cacttctaaa atggaacatt taaagaaagc tgacaaaata 1980 |
| ttaattttga atgaaggtag cagctatttt tatgggacat tttcagaact ccaaaatcta 2040 |
| cagccagact ttagctcaaa actcatggga tgtgattctt tcgaccaatt tagtgcagaa 2100 |
| agaagaaatt caatcctaac tgagacctta caccgtttct cattagaagg agatgctcct 2160 |
| gtctcctgga cagaaacaaa aaaacaatct tttaaacaga ctggagagtt tggggaaaaa 2220 |
| aggaagaatt ctattctcaa tccaatcaac tctatacgaa aattttccat tgtgcaaaag 2280 |
| actcccttac aaatgaatgg catcgaagag gattctgatg agcctttaga gagaaggctg 2340 |
| tccttagtac cagattctga gcagggagag gcgatactgc ctcgcatcag cgtgatcagc 2400 |
| actggcccca cgcttcaggc acgaaggagg cagtctgtcc tgaacctgat gacacactca 2460 |
| gttaaccaag gtcagaacat tcaccgaaag acaacagcat ccacacgaaa agtgtcactg 2520 |
| gcccctcagg caaacttgac tgaactggat atatattcaa gaaggttatc tcaagaaact 2580 |
| ggcttggaaa taagtgaaga aattaacgaa gaagacttaa aggagtgcct ttttgatgat 2640 |
| atggagagca taccagcagt gactacatgg aacacatacc ttcgatatat tactgtccac 2700 |
| aagagcttaa tttttgtgct aatttggtgc ttagtaattt ttctggcaga ggtggctgct 2760 |
| tctttggttg tgctgtggct ccttggaaac actcctcttc aagacaaagg gaatagtact 2820 |
| catagtagaa ataacagcta tgcagtgatt atcaccagca ccagttcgta ttatgtgttt 2880 |
| tacatttacg tgggagtagc cgacactttg cttgctatgg gattcttcag aggtctacca 2940 |
| ctggtgcata ctctaatcac agtgtcgaaa attttacacc acaaaatgtt acattctgtt 3000 |
| cttcaagcac ctatgtcaac cctcaacacg ttgaaagcag gtgggattct taatagattc 3060 |
| tccaaagata tagcaatttt ggatgacctt ctgcctctta ccatatttga cttcatccag 3120 |
| ttgttattaa ttgtgattgg agctatagca gttgtcgcag ttttacaacc ctacatcttt 3180 |
| gttgcaacag tgccagtgat agtggctttt attatgttga gagcatattt cctccaaacc 3240 |
| tcacagcaac tcaaacaact ggaatctgaa ggcaggagtc caattttcac tcatcttgtt 3300 |
| acaagcttaa aaggactatg gacacttcgt gccttcggac ggcagcctta ctttgaaact 3360 |
| ctgttccaca aagctctgaa tttacatact gccaactggt tcttgtacct gtcaacactg 3420 |
| cgctggttcc aaatgagaat agaaatgatt tttgtcatct tcttcattgc tgttaccttc 3480 |
| atttccattt taacaacagg agaaggagaa ggaagagttg gtattatcct gactttagcc 3540 |
| atgaatatca tgagtacatt gcagtgggct gtaaactcca gcatagatgt ggatagcttg 3600 |
| atgcgatctg tgagccgagt ctttaagttc attgacatgc caacagaagg taaacctacc 3660 |
| aagtcaacca aaccatacaa gaatggccaa ctctcgaaag ttatgattat tgagaattca 3720 |
| cacgtgaaga aagatgacat ctggccctca gggggccaaa tgactgtcaa agatctcaca 3780 |
| gcaaaataca cagaaggtgg aaatgccata ttagagaaca tttccttctc aataagtcct 3840 |
| ggccagaggg tgggcctctt gggaagaact ggatcaggga agagtacttt gttatcagct 3900 |
| tttttgagac tactgaacac tgaaggagaa atccagatcg atggtgtgtc ttgggattca 3960 |
| ataactttgc aacagtggag gaaagccttt ggagtgatac cacagaaagt atttattttt 4020 |
| tctggaacat ttagaaaaaa cttggatccc tatgaacagt ggagtgatca agaaatatgg 4080 |
| aaagttgcag atgaggttgg gctcagatct gtgatagaac agtttcctgg gaagcttgac 4140 |
| tttgtccttg tggatggggg ctgtgtccta agccatggcc acaagcagtt gatgtgcttg 4200 |
| gctagatctg ttctcagtaa ggcgaagatc ttgctgcttg atgaacccag tgctcatttg 4260 |
| gatccagtaa cataccaaat aattagaaga actctaaaac aagcatttgc tgattgcaca 4320 |
| gtaattctct gtgaacacag gatagaagca atgctggaat gccaacaatt tttggtcata 4380 |
| gaagagaaca aagtgcggca gtacgattcc atccagaaac tgctgaacga gaggagcctc 4440 |
| ttccggcaag ccatcagccc ctccgacagg gtgaagctct ttccccaccg gaactcaagc 4500 |
| aagtgcaagt ctaagcccca gattgctgct ctgaaagagg agacagaaga agaggtgcaa 4560 |
| gatacaaggc tttagagagc agcataaatg ttgacatggg acatttgctc atggaattgg 4620 |
| agctcgtggg acagtcacct catggaattg gagctcgtgg aacagttacc tctgcctcag 4680 |
| aaaacaagga tgaattaagt ttttttttaa aaaagaaaca tttggtaagg ggaattgagg 4740 |
| acactgatat gggtcttgat aaatggcttc ctggcaatag tcaaattgtg tgaaaggtac 4800 |
| ttcaaatcct tgaagattta ccacttgtgt tttgcaagcc agattttcct gaaaaccctt 4860 |
| gccatgtgct agtaattgga aaggcagctc taaatgtcaa tcagcctagt tgatcagctt 4920 |
| attgtctagt gaaactcgtt aatttgtagt gttggagaag aactgaaatc atacttctta 4980 |
| gggttatgat taagtaatga taactggaaa cttcagcggt ttatataagc ttgtattcct 5040 |
| ttttctctcc tctccccatg atgtttagaa acacaactat attgtttgct aagcattcca 5100 |
| actatctcat ttccaagcaa gtattagaat accacaggaa ccacaagact gcacatcaaa 5160 |
| atatgcccca ttcaacatct agtgagcagt caggaaagag aacttccaga tcctggaaat 5220 |
| cagggttagt attgtccagg tctaccaaaa atctcaatat ttcagataat cacaatacat 5280 |
| cccttacctg ggaaagggct gttataatct ttcacagggg acaggatggt tcccttgatg 5340 |
| aagaagttga tatgcctttt cccaactcca gaaagtgaca agctcacaga cctttgaact 5400 |
| agagtttagc tggaaaagta tgttagtgca aattgtcaca ggacagccct tctttccaca 5460 |
| gaagctccag gtagagggtg tgtaagtaga taggccatgg gcactgtggg tagacacaca 5520 |
| tgaagtccaa gcatttagat gtataggttg atggtggtat gttttcaggc tagatgtatg 5580 |
| tacttcatgc tgtctacact aagagagaat gagagacaca ctgaagaagc accaatcatg 5640 |
| aattagtttt atatgcttct gttttataat tttgtgaagc aaaatttttt ctctaggaaa 5700 |
| tatttatttt aataatgttt caaacatata ttacaatgct gtattttaaa agaatgatta 5760 |
| tgaattacat ttgtataaaa taatttttat atttgaaata ttgacttttt atggcactag 5820 |
| tatttttatg aaatattatg ttaaaactgg gacaggggag aacctagggt gatattaacc 5880 |
| aggggccatg aatcaccttt tggtctggag ggaagccttg gggctgatcg agttgttgcc 5940 |
| cacagctgta tgattcccag ccagacacag cctcttagat gcagttctga agaagatggt 6000 |
| accaccagtc tgactgtttc catcaagggt acactgcctt ctcaactcca aactgactct 6060 |
| taagaagact gcattatatt tattactgta agaaaatatc acttgtcaat aaaatccata 6120 |
| catttgtgt 6129 |
| <200> SEQUENCE CHARACTERISTICS: |
| <210> SEQ ID NO 2 |
| <211> LENGTH: 1480 |
| <212> TYPE: PRT |
| <213> ORGANISM: Homo sapiens |
| <400> SEQUENCE: 2 |
| Met Gln Arg Ser Pro Leu Glu Lys Ala Ser Val Val Ser Lys Leu Phe |
| 1 5 10 15 |
| Phe Ser Trp Thr Arg Pro Ile Leu Arg Lys Gly Tyr Arg Gln Arg Leu |
| 20 25 30 |
| Glu Leu Ser Asp Ile Tyr Gln Ile Pro Ser Val Asp Ser Ala Asp Asn |
| 35 40 45 |
| Leu Ser Glu Lys Leu Glu Arg Glu Trp Asp Arg Glu Leu Ala Ser Lys |
| 50 55 60 |
| Lys Asn Pro Lys Leu Ile Asn Ala Leu Arg Arg Cys Phe Phe Trp Arg |
| 65 70 75 80 |
| Phe Met Phe Tyr Gly Ile Phe Leu Tyr Leu Gly Glu Val Thr Lys Ala |
| 85 90 95 |
| Val Gln Pro Leu Leu Leu Gly Arg Ile Ile Ala Ser Tyr Asp Pro Asp |
| 100 105 110 |
| Asn Lys Glu Glu Arg Ser Ile Ala Ile Tyr Leu Gly Ile Gly Leu Cys |
| 115 120 125 |
| Leu Leu Phe Ile Val Arg Thr Leu Leu Leu His Pro Ala Ile Phe Gly |
| 130 135 140 |
| Leu His His Ile Gly Met Gln Met Arg Ile Ala Met Phe Ser Leu Ile |
| 145 150 155 160 |
| Tyr Lys Lys Thr Leu Lys Leu Ser Ser Arg Val Leu Asp Lys Ile Ser |
| 165 170 175 |
| Ile Gly Gln Leu Val Ser Leu Leu Ser Asn Asn Leu Asn Lys Phe Asp |
| 180 185 190 |
| Glu Gly Leu Ala Leu Ala His Phe Val Trp Ile Ala Pro Leu Gln Val |
| 195 200 205 |
| Ala Leu Leu Met Gly Leu Ile Trp Glu Leu Leu Gln Ala Ser Ala Phe |
| 210 215 220 |
| Cys Gly Leu Gly Phe Leu Ile Val Leu Ala Leu Phe Gln Ala Gly Leu |
| 225 230 235 240 |
| Gly Arg Met Met Met Lys Tyr Arg Asp Gln Arg Ala Gly Lys Ile Ser |
| 245 250 255 |
| Glu Arg Leu Val Ile Thr Ser Glu Met Ile Glu Asn Ile Gln Ser Val |
| 260 265 270 |
| Lys Ala Tyr Cys Trp Glu Glu Ala Met Glu Lys Met Ile Glu Asn Leu |
| 275 280 285 |
| Arg Gln Thr Glu Leu Lys Leu Thr Arg Lys Ala Ala Tyr Val Arg Tyr |
| 290 295 300 |
| Phe Asn Ser Ser Ala Phe Phe Phe Ser Gly Phe Phe Val Val Phe Leu |
| 305 310 315 320 |
| Ser Val Leu Pro Tyr Ala Leu Ile Lys Gly Ile Ile Leu Arg Lys Ile |
| 325 330 335 |
| Phe Thr Thr Ile Ser Phe Cys Ile Val Leu Arg Met Ala Val Thr Arg |
| 340 345 350 |
| Gln Phe Pro Trp Ala Val Gln Thr Trp Tyr Asp Ser Leu Gly Ala Ile |
| 355 360 365 |
| Asn Lys Ile Gln Asp Phe Leu Gln Lys Gln Glu Tyr Lys Thr Leu Glu |
| 370 375 380 |
| Tyr Asn Leu Thr Thr Thr Glu Val Val Met Glu Asn Val Thr Ala Phe |
| 385 390 395 400 |
| Trp Glu Glu Gly Phe Gly Glu Leu Phe Glu Lys Ala Lys Gln Asn Asn |
| 405 410 415 |
| Asn Asn Arg Lys Thr Ser Asn Gly Asp Asp Ser Leu Phe Phe Ser Asn |
| 420 425 430 |
| Phe Ser Leu Leu Gly Thr Pro Val Leu Lys Asp Ile Asn Phe Lys Ile |
| 435 440 445 |
| Glu Arg Gly Gln Leu Leu Ala Val Ala Gly Ser Thr Gly Ala Gly Lys |
| 450 455 460 |
| Thr Ser Leu Leu Met Met Ile Met Gly Glu Leu Glu Pro Ser Glu Gly |
| 465 470 475 480 |
| Lys Ile Lys His Ser Gly Arg Ile Ser Phe Cys Ser Gln Phe Ser Trp |
| 485 490 495 |
| Ile Met Pro Gly Thr Ile Lys Glu Asn Ile Ile Phe Gly Val Ser Tyr |
| 500 505 510 |
| Asp Glu Tyr Arg Tyr Arg Ser Val Ile Lys Ala Cys Gln Leu Glu Glu |
| 515 520 525 |
| Asp Ile Ser Lys Phe Ala Glu Lys Asp Asn Ile Val Leu Gly Glu Gly |
| 530 535 540 |
| Gly Ile Thr Leu Ser Gly Gly Gln Arg Ala Arg Ile Ser Leu Ala Arg |
| 545 550 555 560 |
| Ala Val Tyr Lys Asp Ala Asp Leu Tyr Leu Leu Asp Ser Pro Phe Gly |
| 565 570 575 |
| Tyr Leu Asp Val Leu Thr Glu Lys Glu Ile Phe Glu Ser Cys Val Cys |
| 580 585 590 |
| Lys Leu Met Ala Asn Lys Thr Arg Ile Leu Val Thr Ser Lys Met Glu |
| 595 600 605 |
| His Leu Lys Lys Ala Asp Lys Ile Leu Ile Leu Asn Glu Gly Ser Ser |
| 610 615 620 |
| Tyr Phe Tyr Gly Thr Phe Ser Glu Leu Gln Asn Leu Gln Pro Asp Phe |
| 625 630 635 640 |
| Ser Ser Lys Leu Met Gly Cys Asp Ser Phe Asp Gln Phe Ser Ala Glu |
| 645 650 655 |
| Arg Arg Asn Ser Ile Leu Thr Glu Thr Leu His Arg Phe Ser Leu Glu |
| 660 665 670 |
| Gly Asp Ala Pro Val Ser Trp Thr Glu Thr Lys Lys Gln Ser Phe Lys |
| 675 680 685 |
| Gln Thr Gly Glu Phe Gly Glu Lys Arg Lys Asn Ser Ile Leu Asn Pro |
| 690 695 700 |
| Ile Asn Ser Ile Arg Lys Phe Ser Ile Val Gln Lys Thr Pro Leu Gln |
| 705 710 715 720 |
| Met Asn Gly Ile Glu Glu Asp Ser Asp Glu Pro Leu Glu Arg Arg Leu |
| 725 730 735 |
| Ser Leu Val Pro Asp Ser Glu Gln Gly Glu Ala Ile Leu Pro Arg Ile |
| 740 745 750 |
| Ser Val Ile Ser Thr Gly Pro Thr Leu Gln Ala Arg Arg Arg Gln Ser |
| 755 760 765 |
| Val Leu Asn Leu Met Thr His Ser Val Asn Gln Gly Gln Asn Ile His |
| 770 775 780 |
| Arg Lys Thr Thr Ala Ser Thr Arg Lys Val Ser Leu Ala Pro Gln Ala |
| 785 790 795 800 |
| Asn Leu Thr Glu Leu Asp Ile Tyr Ser Arg Arg Leu Ser Gln Glu Thr |
| 805 810 815 |
| Gly Leu Glu Ile Ser Glu Glu Ile Asn Glu Glu Asp Leu Lys Glu Cys |
| 820 825 830 |
| Leu Phe Asp Asp Met Glu Ser Ile Pro Ala Val Thr Thr Trp Asn Thr |
| 835 840 845 |
| Tyr Leu Arg Tyr Ile Thr Val His Lys Ser Leu Ile Phe Val Leu Ile |
| 850 855 860 |
| Trp Cys Leu Val Ile Phe Leu Ala Glu Val Ala Ala Ser Leu Val Val |
| 865 870 875 880 |
| Leu Trp Leu Leu Gly Asn Thr Pro Leu Gln Asp Lys Gly Asn Ser Thr |
| 885 890 895 |
| His Ser Arg Asn Asn Ser Tyr Ala Val Ile Ile Thr Ser Thr Ser Ser |
| 900 905 910 |
| Tyr Tyr Val Phe Tyr Ile Tyr Val Gly Val Ala Asp Thr Leu Leu Ala |
| 915 920 925 |
| Met Gly Phe Phe Arg Gly Leu Pro Leu Val His Thr Leu Ile Thr Val |
| 930 935 940 |
| Ser Lys Ile Leu His His Lys Met Leu His Ser Val Leu Gln Ala Pro |
| 945 950 955 960 |
| Met Ser Thr Leu Asn Thr Leu Lys Ala Gly Gly Ile Leu Asn Arg Phe |
| 965 970 975 |
| Ser Lys Asp Ile Ala Ile Leu Asp Asp Leu Leu Pro Leu Thr Ile Phe |
| 980 985 990 |
| Asp Phe Ile Gln Leu Leu Leu Ile Val Ile Gly Ala Ile Ala Val Val |
| 995 1000 1005 |
| Ala Val Leu Gln Pro Tyr Ile Phe Val Ala Thr Val Pro Val Ile Val |
| 1010 1015 1020 |
| Ala Phe Ile Met Leu Arg Ala Tyr Phe Leu Gln Thr Ser Gln Gln Leu |
| 1025 1030 1035 1040 |
| Lys Gln Leu Glu Ser Glu Gly Arg Ser Pro Ile Phe Thr His Leu Val |
| 1045 1050 1055 |
| Thr Ser Leu Lys Gly Leu Trp Thr Leu Arg Ala Phe Gly Arg Gln Pro |
| 1060 1065 1070 |
| Tyr Phe Glu Thr Leu Phe His Lys Ala Leu Asn Leu His Thr Ala Asn |
| 1075 1080 1085 |
| Trp Phe Leu Tyr Leu Ser Thr Leu Arg Trp Phe Gln Met Arg Ile Glu |
| 1090 1095 1100 |
| Met Ile Phe Val Ile Phe Phe Ile Ala Val Thr Phe Ile Ser Ile Leu |
| 1105 1110 1115 1120 |
| Thr Thr Gly Glu Gly Glu Gly Arg Val Gly Ile Ile Leu Thr Leu Ala |
| 1125 1130 1135 |
| Met Asn Ile Met Ser Thr Leu Gln Trp Ala Val Asn Ser Ser Ile Asp |
| 1140 1145 1150 |
| Val Asp Ser Leu Met Arg Ser Val Ser Arg Val Phe Lys Phe Ile Asp |
| 1155 1160 1165 |
| Met Pro Thr Glu Gly Lys Pro Thr Lys Ser Thr Lys Pro Tyr Lys Asn |
| 1170 1175 1180 |
| Gly Gln Leu Ser Lys Val Met Ile Ile Glu Asn Ser His Val Lys Lys |
| 1185 1190 1195 1200 |
| Asp Asp Ile Trp Pro Ser Gly Gly Gln Met Thr Val Lys Asp Leu Thr |
| 1205 1210 1215 |
| Ala Lys Tyr Thr Glu Gly Gly Asn Ala Ile Leu Glu Asn Ile Ser Phe |
| 1220 1225 1230 |
| Ser Ile Ser Pro Gly Gln Arg Val Gly Leu Leu Gly Arg Thr Gly Ser |
| 1235 1240 1245 |
| Gly Lys Ser Thr Leu Leu Ser Ala Phe Leu Arg Leu Leu Asn Thr Glu |
| 1250 1255 1260 |
| Gly Glu Ile Gln Ile Asp Gly Val Ser Trp Asp Ser Ile Thr Leu Gln |
| 1265 1270 1275 1280 |
| Gln Trp Arg Lys Ala Phe Gly Val Ile Pro Gln Lys Val Phe Ile Phe |
| 1285 1290 1295 |
| Ser Gly Thr Phe Arg Lys Asn Leu Asp Pro Tyr Glu Gln Trp Ser Asp |
| 1300 1305 1310 |
| Gln Glu Ile Trp Lys Val Ala Asp Glu Val Gly Leu Arg Ser Val Ile |
| 1315 1320 1325 |
| Glu Gln Phe Pro Gly Lys Leu Asp Phe Val Leu Val Asp Gly Gly Cys |
| 1330 1335 1340 |
| Val Leu Ser His Gly His Lys Gln Leu Met Cys Leu Ala Arg Ser Val |
| 1345 1350 1355 1360 |
| Leu Ser Lys Ala Lys Ile Leu Leu Leu Asp Glu Pro Ser Ala His Leu |
| 1365 1370 1375 |
| Asp Pro Val Thr Tyr Gln Ile Ile Arg Arg Thr Leu Lys Gln Ala Phe |
| 1380 1385 1390 |
| Ala Asp Cys Thr Val Ile Leu Cys Glu His Arg Ile Glu Ala Met Leu |
| 1395 1400 1405 |
| Glu Cys Gln Gln Phe Leu Val Ile Glu Glu Asn Lys Val Arg Gln Tyr |
| 1410 1415 1420 |
| Asp Ser Ile Gln Lys Leu Leu Asn Glu Arg Ser Leu Phe Arg Gln Ala |
| 1425 1430 1435 1440 |
| Ile Ser Pro Ser Asp Arg Val Lys Leu Phe Pro His Arg Asn Ser Ser |
| 1445 1450 1455 |
| Lys Cys Lys Ser Lys Pro Gln Ile Ala Ala Leu Lys Glu Glu Thr Glu |
| 1460 1465 1470 |
| Glu Glu Val Gln Asp Thr Arg Leu |
| 1475 1480 |
| <200> SEQUENCE CHARACTERISTICS: |
| <210> SEQ ID NO 3 |
| <211> LENGTH: 6126 |
| <212> TYPE: DNA |
| <213> ORGANISM: Homo sapiens |
| <400> SEQUENCE: 3 |
| aattggaagc aaatgacatc acagcaggtc agagaaaaag ggttgagcgg caggcaccca 60 |
| gagtagtagg tctttggcat taggagcttg agcccagacg gccctagcag ggaccccagc 120 |
| gcccgagaga ccatgcagag gtcgcctctg gaaaaggcca gcgttgtctc caaacttttt 180 |
| ttcagctgga ccagaccaat tttgaggaaa ggatacagac agcgcctgga attgtcagac 240 |
| atataccaaa tcccttctgt tgattctgct gacaatctat ctgaaaaatt ggaaagagaa 300 |
| tgggatagag agctggcttc aaagaaaaat cctaaactca ttaatgccct tcggcgatgt 360 |
| tttttctgga gatttatgtt ctatggaatc tttttatatt taggggaagt caccaaagca 420 |
| gtacagcctc tcttactggg aagaatcata gcttcctatg acccggataa caaggaggaa 480 |
| cgctctatcg cgatttatct aggcataggc ttatgccttc tctttattgt gaggacactg 540 |
| ctcctacacc cagccatttt tggccttcat cacattggaa tgcagatgag aatagctatg 600 |
| tttagtttga tttataagaa gactttaaag ctgtcaagcc gtgttctaga taaaataagt 660 |
| attggacaac ttgttagtct cctttccaac aacctgaaca aatttgatga aggacttgca 720 |
| ttggcacatt tcgtgtggat cgctcctttg caagtggcac tcctcatggg gctaatctgg 780 |
| gagttgttac aggcgtctgc cttctgtgga cttggtttcc tgatagtcct tgcccttttt 840 |
| caggctgggc tagggagaat gatgatgaag tacagagatc agagagctgg gaagatcagt 900 |
| gaaagacttg tgattacctc agaaatgatt gaaaatatcc aatctgttaa ggcatactgc 960 |
| tgggaagaag caatggaaaa aatgattgaa aacttaagac aaacagaact gaaactgact 1020 |
| cggaaggcag cctatgtgag atacttcaat agctcagcct tcttcttctc agggttcttt 1080 |
| gtggtgtttt tatctgtgct tccctatgca ctaatcaaag gaatcatcct ccggaaaata 1140 |
| ttcaccacca tctcattctg cattgttctg cgcatggcgg tcactcggca atttccctgg 1200 |
| gctgtacaaa catggtatga ctctcttgga gcaataaaca aaatacagga tttcttacaa 1260 |
| aagcaagaat ataagacatt ggaatataac ttaacgacta cagaagtagt gatggagaat 1320 |
| gtaacagcct tctgggagga gggatttggg gaattatttg agaaagcaaa acaaaacaat 1380 |
| aacaatagaa aaacttctaa tggtgatgac agcctcttct tcagtaattt ctcacttctt 1440 |
| ggtactcctg tcctgaaaga tattaatttc aagatagaaa gaggacagtt gttggcggtt 1500 |
| gctggatcca ctggagcagg caagacttca cttctaatga tgattatggg agaactggag 1560 |
| ccttcagagg gtaaaattaa gcacagtgga agaatttcat tctgttctca gttttcctgg 1620 |
| attatgcctg gcaccattaa agaaaatatc atcggtgttt cctatgatga atatagatac 1680 |
| agaagcgtca tcaaagcatg ccaactagaa gaggacatct ccaagtttgc agagaaagac 1740 |
| aatatagttc ttggagaagg tggaatcaca ctgagtggag gtcaacgagc aagaatttct 1800 |
| ttagcaagag cagtatacaa agatgctgat ttgtatttat tagactctcc ttttggatac 1860 |
| ctagatgttt taacagaaaa agaaatattt gaaagctgtg tctgtaaact gatggctaac 1920 |
| aaaactagga ttttggtcac ttctaaaatg gaacatttaa agaaagctga caaaatatta 1980 |
| attttgaatg aaggtagcag ctatttttat gggacatttt cagaactcca aaatctacag 2040 |
| ccagacttta gctcaaaact catgggatgt gattctttcg accaatttag tgcagaaaga 2100 |
| agaaattcaa tcctaactga gaccttacac cgtttctcat tagaaggaga tgctcctgtc 2160 |
| tcctggacag aaacaaaaaa acaatctttt aaacagactg gagagtttgg ggaaaaaagg 2220 |
| aagaattcta ttctcaatcc aatcaactct atacgaaaat tttccattgt gcaaaagact 2280 |
| cccttacaaa tgaatggcat cgaagaggat tctgatgagc ctttagagag aaggctgtcc 2340 |
| ttagtaccag attctgagca gggagaggcg atactgcctc gcatcagcgt gatcagcact 2400 |
| ggccccacgc ttcaggcacg aaggaggcag tctgtcctga acctgatgac acactcagtt 2460 |
| aaccaaggtc agaacattca ccgaaagaca acagcatcca cacgaaaagt gtcactggcc 2520 |
| cctcaggcaa acttgactga actggatata tattcaagaa ggttatctca agaaactggc 2580 |
| ttggaaataa gtgaagaaat taacgaagaa gacttaaagg agtgcctttt tgatgatatg 2640 |
| gagagcatac cagcagtgac tacatggaac acataccttc gatatattac tgtccacaag 2700 |
| agcttaattt ttgtgctaat ttggtgctta gtaatttttc tggcagaggt ggctgcttct 2760 |
| ttggttgtgc tgtggctcct tggaaacact cctcttcaag acaaagggaa tagtactcat 2820 |
| agtagaaata acagctatgc agtgattatc accagcacca gttcgtatta tgtgttttac 2880 |
| atttacgtgg gagtagccga cactttgctt gctatgggat tcttcagagg tctaccactg 2940 |
| gtgcatactc taatcacagt gtcgaaaatt ttacaccaca aaatgttaca ttctgttctt 3000 |
| caagcaccta tgtcaaccct caacacgttg aaagcaggtg ggattcttaa tagattctcc 3060 |
| aaagatatag caattttgga tgaccttctg cctcttacca tatttgactt catccagttg 3120 |
| ttattaattg tgattggagc tatagcagtt gtcgcagttt tacaacccta catctttgtt 3180 |
| gcaacagtgc cagtgatagt ggcttttatt atgttgagag catatttcct ccaaacctca 3240 |
| cagcaactca aacaactgga atctgaaggc aggagtccaa ttttcactca tcttgttaca 3300 |
| agcttaaaag gactatggac acttcgtgcc ttcggacggc agccttactt tgaaactctg 3360 |
| ttccacaaag ctctgaattt acatactgcc aactggttct tgtacctgtc aacactgcgc 3420 |
| tggttccaaa tgagaataga aatgattttt gtcatcttct tcattgctgt taccttcatt 3480 |
| tccattttaa caacaggaga aggagaagga agagttggta ttatcctgac tttagccatg 3540 |
| aatatcatga gtacattgca gtgggctgta aactccagca tagatgtgga tagcttgatg 3600 |
| cgatctgtga gccgagtctt taagttcatt gacatgccaa cagaaggtaa acctaccaag 3660 |
| tcaaccaaac catacaagaa tggccaactc tcgaaagtta tgattattga gaattcacac 3720 |
| gtgaagaaag atgacatctg gccctcaggg ggccaaatga ctgtcaaaga tctcacagca 3780 |
| aaatacacag aaggtggaaa tgccatatta gagaacattt ccttctcaat aagtcctggc 3840 |
| cagagggtgg gcctcttggg aagaactgga tcagggaaga gtactttgtt atcagctttt 3900 |
| ttgagactac tgaacactga aggagaaatc cagatcgatg gtgtgtcttg ggattcaata 3960 |
| actttgcaac agtggaggaa agcctttgga gtgataccac agaaagtatt tattttttct 4020 |
| ggaacattta gaaaaaactt ggatccctat gaacagtgga gtgatcaaga aatatggaaa 4080 |
| gttgcagatg aggttgggct cagatctgtg atagaacagt ttcctgggaa gcttgacttt 4140 |
| gtccttgtgg atgggggctg tgtcctaagc catggccaca agcagttgat gtgcttggct 4200 |
| agatctgttc tcagtaaggc gaagatcttg ctgcttgatg aacccagtgc tcatttggat 4260 |
| ccagtaacat accaaataat tagaagaact ctaaaacaag catttgctga ttgcacagta 4320 |
| attctctgtg aacacaggat agaagcaatg ctggaatgcc aacaattttt ggtcatagaa 4380 |
| gagaacaaag tgcggcagta cgattccatc cagaaactgc tgaacgagag gagcctcttc 4440 |
| cggcaagcca tcagcccctc cgacagggtg aagctctttc cccaccggaa ctcaagcaag 4500 |
| tgcaagtcta agccccagat tgctgctctg aaagaggaga cagaagaaga ggtgcaagat 4560 |
| acaaggcttt agagagcagc ataaatgttg acatgggaca tttgctcatg gaattggagc 4620 |
| tcgtgggaca gtcacctcat ggaattggag ctcgtggaac agttacctct gcctcagaaa 4680 |
| acaaggatga attaagtttt tttttaaaaa agaaacattt ggtaagggga attgaggaca 4740 |
| ctgatatggg tcttgataaa tggcttcctg gcaatagtca aattgtgtga aaggtacttc 4800 |
| aaatccttga agatttacca cttgtgtttt gcaagccaga ttttcctgaa aacccttgcc 4860 |
| atgtgctagt aattggaaag gcagctctaa atgtcaatca gcctagttga tcagcttatt 4920 |
| gtctagtgaa actcgttaat ttgtagtgtt ggagaagaac tgaaatcata cttcttaggg 4980 |
| ttatgattaa gtaatgataa ctggaaactt cagcggttta tataagcttg tattcctttt 5040 |
| tctctcctct ccccatgatg tttagaaaca caactatatt gtttgctaag cattccaact 5100 |
| atctcatttc caagcaagta ttagaatacc acaggaacca caagactgca catcaaaata 5160 |
| tgccccattc aacatctagt gagcagtcag gaaagagaac ttccagatcc tggaaatcag 5220 |
| ggttagtatt gtccaggtct accaaaaatc tcaatatttc agataatcac aatacatccc 5280 |
| ttacctggga aagggctgtt ataatctttc acaggggaca ggatggttcc cttgatgaag 5340 |
| aagttgatat gccttttccc aactccagaa agtgacaagc tcacagacct ttgaactaga 5400 |
| gtttagctgg aaaagtatgt tagtgcaaat tgtcacagga cagcccttct ttccacagaa 5460 |
| gctccaggta gagggtgtgt aagtagatag gccatgggca ctgtgggtag acacacatga 5520 |
| agtccaagca tttagatgta taggttgatg gtggtatgtt ttcaggctag atgtatgtac 5580 |
| ttcatgctgt ctacactaag agagaatgag agacacactg aagaagcacc aatcatgaat 5640 |
| tagttttata tgcttctgtt ttataatttt gtgaagcaaa attttttctc taggaaatat 5700 |
| ttattttaat aatgtttcaa acatatatta caatgctgta ttttaaaaga atgattatga 5760 |
| attacatttg tataaaataa tttttatatt tgaaatattg actttttatg gcactagtat 5820 |
| ttttatgaaa tattatgtta aaactgggac aggggagaac ctagggtgat attaaccagg 5880 |
| ggccatgaat caccttttgg tctggaggga agccttgggg ctgatcgagt tgttgcccac 5940 |
| agctgtatga ttcccagcca gacacagcct cttagatgca gttctgaaga agatggtacc 6000 |
| accagtctga ctgtttccat caagggtaca ctgccttctc aactccaaac tgactcttaa 6060 |
| gaagactgca ttatatttat tactgtaaga aaatatcact tgtcaataaa atccatacat 6120 |
| ttgtgt 6126 |
| <200> SEQUENCE CHARACTERISTICS: |
| <210> SEQ ID NO 4 |
| <211> LENGTH: 1479 |
| <212> TYPE: PRT |
| <213> ORGANISM: Homo sapiens |
| <400> SEQUENCE: 4 |
| Met Gln Arg Ser Pro Leu Glu Lys Ala Ser Val Val Ser Lys Leu Phe |
| 1 5 10 15 |
| Phe Ser Trp Thr Arg Pro Ile Leu Arg Lys Gly Tyr Arg Gln Arg Leu |
| 20 25 30 |
| Glu Leu Ser Asp Ile Tyr Gln Ile Pro Ser Val Asp Ser Ala Asp Asn |
| 35 40 45 |
| Leu Ser Glu Lys Leu Glu Arg Glu Trp Asp Arg Glu Leu Ala Ser Lys |
| 50 55 60 |
| Lys Asn Pro Lys Leu Ile Asn Ala Leu Arg Arg Cys Phe Phe Trp Arg |
| 65 70 75 80 |
| Phe Met Phe Tyr Gly Ile Phe Leu Tyr Leu Gly Glu Val Thr Lys Ala |
| 85 90 95 |
| Val Gln Pro Leu Leu Leu Gly Arg Ile Ile Ala Ser Tyr Asp Pro Asp |
| 100 105 110 |
| Asn Lys Glu Glu Arg Ser Ile Ala Ile Tyr Leu Gly Ile Gly Leu Cys |
| 115 120 125 |
| Leu Leu Phe Ile Val Arg Thr Leu Leu Leu His Pro Ala Ile Phe Gly |
| 130 135 140 |
| Leu His His Ile Gly Met Gln Met Arg Ile Ala Met Phe Ser Leu Ile |
| 145 150 155 160 |
| Tyr Lys Lys Thr Leu Lys Leu Ser Ser Arg Val Leu Asp Lys Ile Ser |
| 165 170 175 |
| Ile Gly Gln Leu Val Ser Leu Leu Ser Asn Asn Leu Asn Lys Phe Asp |
| 180 185 190 |
| Glu Gly Leu Ala Leu Ala His Phe Val Trp Ile Ala Pro Leu Gln Val |
| 195 200 205 |
| Ala Leu Leu Met Gly Leu Ile Trp Glu Leu Leu Gln Ala Ser Ala Phe |
| 210 215 220 |
| Cys Gly Leu Gly Phe Leu Ile Val Leu Ala Leu Phe Gln Ala Gly Leu |
| 225 230 235 240 |
| Gly Arg Met Met Met Lys Tyr Arg Asp Gln Arg Ala Gly Lys Ile Ser |
| 245 250 255 |
| Glu Arg Leu Val Ile Thr Ser Glu Met Ile Glu Asn Ile Gln Ser Val |
| 260 265 270 |
| Lys Ala Tyr Cys Trp Glu Glu Ala Met Glu Lys Met Ile Glu Asn Leu |
| 275 280 285 |
| Arg Gln Thr Glu Leu Lys Leu Thr Arg Lys Ala Ala Tyr Val Arg Tyr |
| 290 295 300 |
| Phe Asn Ser Ser Ala Phe Phe Phe Ser Gly Phe Phe Val Val Phe Leu |
| 305 310 315 320 |
| Ser Val Leu Pro Tyr Ala Leu Ile Lys Gly Ile Ile Leu Arg Lys Ile |
| 325 330 335 |
| Phe Thr Thr Ile Ser Phe Cys Ile Val Leu Arg Met Ala Val Thr Arg |
| 340 345 350 |
| Gln Phe Pro Trp Ala Val Gln Thr Trp Tyr Asp Ser Leu Gly Ala Ile |
| 355 360 365 |
| Asn Lys Ile Gln Asp Phe Leu Gln Lys Gln Glu Tyr Lys Thr Leu Glu |
| 370 375 380 |
| Tyr Asn Leu Thr Thr Thr Glu Val Val Met Glu Asn Val Thr Ala Phe |
| 385 390 395 400 |
| Trp Glu Glu Gly Phe Gly Glu Leu Phe Glu Lys Ala Lys Gln Asn Asn |
| 405 410 415 |
| Asn Asn Arg Lys Thr Ser Asn Gly Asp Asp Ser Leu Phe Phe Ser Asn |
| 420 425 430 |
| Phe Ser Leu Leu Gly Thr Pro Val Leu Lys Asp Ile Asn Phe Lys Ile |
| 435 440 445 |
| Glu Arg Gly Gln Leu Leu Ala Val Ala Gly Ser Thr Gly Ala Gly Lys |
| 450 455 460 |
| Thr Ser Leu Leu Met Met Ile Met Gly Glu Leu Glu Pro Ser Glu Gly |
| 465 470 475 480 |
| Lys Ile Lys His Ser Gly Arg Ile Ser Phe Cys Ser Gln Phe Ser Trp |
| 485 490 495 |
| Ile Met Pro Gly Thr Ile Lys Glu Asn Ile Ile Gly Val Ser Tyr Asp |
| 500 505 510 |
| Glu Tyr Arg Tyr Arg Ser Val Ile Lys Ala Cys Gln Leu Glu Glu Asp |
| 515 520 525 |
| Ile Ser Lys Phe Ala Glu Lys Asp Asn Ile Val Leu Gly Glu Gly Gly |
| 530 535 540 |
| Ile Thr Leu Ser Gly Gly Gln Arg Ala Arg Ile Ser Leu Ala Arg Ala |
| 545 550 555 560 |
| Val Tyr Lys Asp Ala Asp Leu Tyr Leu Leu Asp Ser Pro Phe Gly Tyr |
| 565 570 575 |
| Leu Asp Val Leu Thr Glu Lys Glu Ile Phe Glu Ser Cys Val Cys Lys |
| 580 585 590 |
| Leu Met Ala Asn Lys Thr Arg Ile Leu Val Thr Ser Lys Met Glu His |
| 595 600 605 |
| Leu Lys Lys Ala Asp Lys Ile Leu Ile Leu Asn Glu Gly Ser Ser Tyr |
| 610 615 620 |
| Phe Tyr Gly Thr Phe Ser Glu Leu Gln Asn Leu Gln Pro Asp Phe Ser |
| 625 630 635 640 |
| Ser Lys Leu Met Gly Cys Asp Ser Phe Asp Gln Phe Ser Ala Glu Arg |
| 645 650 655 |
| Arg Asn Ser Ile Leu Thr Glu Thr Leu His Arg Phe Ser Leu Glu Gly |
| 660 665 670 |
| Asp Ala Pro Val Ser Trp Thr Glu Thr Lys Lys Gln Ser Phe Lys Gln |
| 675 680 685 |
| Thr Gly Glu Phe Gly Glu Lys Arg Lys Asn Ser Ile Leu Asn Pro Ile |
| 690 695 700 |
| Asn Ser Ile Arg Lys Phe Ser Ile Val Gln Lys Thr Pro Leu Gln Met |
| 705 710 715 720 |
| Asn Gly Ile Glu Glu Asp Ser Asp Glu Pro Leu Glu Arg Arg Leu Ser |
| 725 730 735 |
| Leu Val Pro Asp Ser Glu Gln Gly Glu Ala Ile Leu Pro Arg Ile Ser |
| 740 745 750 |
| Val Ile Ser Thr Gly Pro Thr Leu Gln Ala Arg Arg Arg Gln Ser Val |
| 755 760 765 |
| Leu Asn Leu Met Thr His Ser Val Asn Gln Gly Gln Asn Ile His Arg |
| 770 775 780 |
| Lys Thr Thr Ala Ser Thr Arg Lys Val Ser Leu Ala Pro Gln Ala Asn |
| 785 790 795 800 |
| Leu Thr Glu Leu Asp Ile Tyr Ser Arg Arg Leu Ser Gln Glu Thr Gly |
| 805 810 815 |
| Leu Glu Ile Ser Glu Glu Ile Asn Glu Glu Asp Leu Lys Glu Cys Leu |
| 820 825 830 |
| Phe Asp Asp Met Glu Ser Ile Pro Ala Val Thr Thr Trp Asn Thr Tyr |
| 835 840 845 |
| Leu Arg Tyr Ile Thr Val His Lys Ser Leu Ile Phe Val Leu Ile Trp |
| 850 855 860 |
| Cys Leu Val Ile Phe Leu Ala Glu Val Ala Ala Ser Leu Val Val Leu |
| 865 870 875 880 |
| Trp Leu Leu Gly Asn Thr Pro Leu Gln Asp Lys Gly Asn Ser Thr His |
| 885 890 895 |
| Ser Arg Asn Asn Ser Tyr Ala Val Ile Ile Thr Ser Thr Ser Ser Tyr |
| 900 905 910 |
| Tyr Val Phe Tyr Ile Tyr Val Gly Val Ala Asp Thr Leu Leu Ala Met |
| 915 920 925 |
| Gly Phe Phe Arg Gly Leu Pro Leu Val His Thr Leu Ile Thr Val Ser |
| 930 935 940 |
| Lys Ile Leu His His Lys Met Leu His Ser Val Leu Gln Ala Pro Met |
| 945 950 955 960 |
| Ser Thr Leu Asn Thr Leu Lys Ala Gly Gly Ile Leu Asn Arg Phe Ser |
| 965 970 975 |
| Lys Asp Ile Ala Ile Leu Asp Asp Leu Leu Pro Leu Thr Ile Phe Asp |
| 980 985 990 |
| Phe Ile Gln Leu Leu Leu Ile Val Ile Gly Ala Ile Ala Val Val Ala |
| 995 1000 1005 |
| Val Leu Gln Pro Tyr Ile Phe Val Ala Thr Val Pro Val Ile Val Ala |
| 1010 1015 1020 |
| Phe Ile Met Leu Arg Ala Tyr Phe Leu Gln Thr Ser Gln Gln Leu Lys |
| 1025 1030 1035 1040 |
| Gln Leu Glu Ser Glu Gly Arg Ser Pro Ile Phe Thr His Leu Val Thr |
| 1045 1050 1055 |
| Ser Leu Lys Gly Leu Trp Thr Leu Arg Ala Phe Gly Arg Gln Pro Tyr |
| 1060 1065 1070 |
| Phe Glu Thr Leu Phe His Lys Ala Leu Asn Leu His Thr Ala Asn Trp |
| 1075 1080 1085 |
| Phe Leu Tyr Leu Ser Thr Leu Arg Trp Phe Gln Met Arg Ile Glu Met |
| 1090 1095 1100 |
| Ile Phe Val Ile Phe Phe Ile Ala Val Thr Phe Ile Ser Ile Leu Thr |
| 1105 1110 1115 1120 |
| Thr Gly Glu Gly Glu Gly Arg Val Gly Ile Ile Leu Thr Leu Ala Met |
| 1125 1130 1135 |
| Asn Ile Met Ser Thr Leu Gln Trp Ala Val Asn Ser Ser Ile Asp Val |
| 1140 1145 1150 |
| Asp Ser Leu Met Arg Ser Val Ser Arg Val Phe Lys Phe Ile Asp Met |
| 1155 1160 1165 |
| Pro Thr Glu Gly Lys Pro Thr Lys Ser Thr Lys Pro Tyr Lys Asn Gly |
| 1170 1175 1180 |
| Gln Leu Ser Lys Val Met Ile Ile Glu Asn Ser His Val Lys Lys Asp |
| 1185 1190 1195 1200 |
| Asp Ile Trp Pro Ser Gly Gly Gln Met Thr Val Lys Asp Leu Thr Ala |
| 1205 1210 1215 |
| Lys Tyr Thr Glu Gly Gly Asn Ala Ile Leu Glu Asn Ile Ser Phe Ser |
| 1220 1225 1230 |
| Ile Ser Pro Gly Gln Arg Val Gly Leu Leu Gly Arg Thr Gly Ser Gly |
| 1235 1240 1245 |
| Lys Ser Thr Leu Leu Ser Ala Phe Leu Arg Leu Leu Asn Thr Glu Gly |
| 1250 1255 1260 |
| Glu Ile Gln Ile Asp Gly Val Ser Trp Asp Ser Ile Thr Leu Gln Gln |
| 1265 1270 1275 1280 |
| Trp Arg Lys Ala Phe Gly Val Ile Pro Gln Lys Val Phe Ile Phe Ser |
| 1285 1290 1295 |
| Gly Thr Phe Arg Lys Asn Leu Asp Pro Tyr Glu Gln Trp Ser Asp Gln |
| 1300 1305 1310 |
| Glu Ile Trp Lys Val Ala Asp Glu Val Gly Leu Arg Ser Val Ile Glu |
| 1315 1320 1325 |
| Gln Phe Pro Gly Lys Leu Asp Phe Val Leu Val Asp Gly Gly Cys Val |
| 1330 1335 1340 |
| Leu Ser His Gly His Lys Gln Leu Met Cys Leu Ala Arg Ser Val Leu |
| 1345 1350 1355 1360 |
| Ser Lys Ala Lys Ile Leu Leu Leu Asp Glu Pro Ser Ala His Leu Asp |
| 1365 1370 1375 |
| Pro Val Thr Tyr Gln Ile Ile Arg Arg Thr Leu Lys Gln Ala Phe Ala |
| 1380 1385 1390 |
| Asp Cys Thr Val Ile Leu Cys Glu His Arg Ile Glu Ala Met Leu Glu |
| 1395 1400 1405 |
| Cys Gln Gln Phe Leu Val Ile Glu Glu Asn Lys Val Arg Gln Tyr Asp |
| 1410 1415 1420 |
| Ser Ile Gln Lys Leu Leu Asn Glu Arg Ser Leu Phe Arg Gln Ala Ile |
| 1425 1430 1435 1440 |
| Ser Pro Ser Asp Arg Val Lys Leu Phe Pro His Arg Asn Ser Ser Lys |
| 1445 1450 1455 |
| Cys Lys Ser Lys Pro Gln Ile Ala Ala Leu Lys Glu Glu Thr Glu Glu |
| 1460 1465 1470 |
| Glu Val Gln Asp Thr Arg Leu |
| 1475 |
| <200> SEQUENCE CHARACTERISTICS: |
| <210> SEQ ID NO 5 |
| <211> LENGTH: 6129 |
| <212> TYPE: DNA |
| <213> ORGANISM: Homo sapiens |
| <400> SEQUENCE: 5 |
| aattggaagc aaatgacatc acagcaggtc agagaaaaag ggttgagcgg caggcaccca 60 |
| gagtagtagg tctttggcat taggagcttg agcccagacg gccctagcag ggaccccagc 120 |
| gcccgagaga ccatgcagag gtcgcctctg gaaaaggcca gcgttgtctc caaacttttt 180 |
| ttcagctgga ccagaccaat tttgaggaaa ggatacagac agcgcctgga attgtcagac 240 |
| atataccaaa tcccttctgt tgattctgct gacaatctat ctgaaaaatt ggaaagagaa 300 |
| tgggatagag agctggcttc aaagaaaaat cctaaactca ttaatgccct tcggcgatgt 360 |
| tttttctgga gatttatgtt ctatggaatc tttttatatt taggggaagt caccaaagca 420 |
| gtacagcctc tcttactggg aagaatcata gcttcctatg acccggataa caaggaggaa 480 |
| cgctctatcg cgatttatct aggcataggc ttatgccttc tctttattgt gaggacactg 540 |
| ctcctacacc cagccatttt tggccttcat cacattggaa tgcagatgag aatagctatg 600 |
| tttagtttga tttataagaa gactttaaag ctgtcaagcc gtgttctaga taaaataagt 660 |
| attggacaac ttgttagtct cctttccaac aacctgaaca aatttgatga aggacttgca 720 |
| ttggcacatt tcgtgtggat cgctcctttg caagtggcac tcctcatggg gctaatctgg 780 |
| gagttgttac aggcgtctgc cttctgtgga cttggtttcc tgatagtcct tgcccttttt 840 |
| caggctgggc tagggagaat gatgatgaag tacagagatc agagagctgg gaagatcagt 900 |
| gaaagacttg tgattacctc agaaatgatt gaaaatatcc aatctgttaa ggcatactgc 960 |
| tgggaagaag caatggaaaa aatgattgaa aacttaagac aaacagaact gaaactgact 1020 |
| cggaaggcag cctatgtgag atacttcaat agctcagcct tcttcttctc agggttcttt 1080 |
| gtggtgtttt tatctgtgct tccctatgca ctaatcaaag gaatcatcct ccggaaaata 1140 |
| ttcaccacca tctcattctg cattgttctg cgcatggcgg tcactcggca atttccctgg 1200 |
| gctgtacaaa catggtatga ctctcttgga gcaataaaca aaatacagga tttcttacaa 1260 |
| aagcaagaat ataagacatt ggaatataac ttaacgacta cagaagtagt gatggagaat 1320 |
| gtaacagcct tctgggagga gggatttggg gaattatttg agaaagcaaa acaaaacaat 1380 |
| aacaatagaa aaacttctaa tggtgatgac agcctcttct tcagtaattt ctcacttctt 1440 |
| ggtactcctg tcctgaaaga tattaatttc aagatagaaa gaggacagtt gttggcggtt 1500 |
| gctggatcca ctggagcagg caagacttca cttctaatga tgattatggg agaactggag 1560 |
| ccttcagagg gtaaaattaa gcacagtgga agaatttcat tctgttctca gttttcctgg 1620 |
| attatgcctg gcaccattaa agaaaatatc atctttggtg tttcctatga tgaatataga 1680 |
| tacagaagcg tcatcaaagc atgccaacta gaagaggaca tctccaagtt tgcagagaaa 1740 |
| gacaatatag ttcttggaga aggtggaatc acactgagtg gagaycaacg agcaagaatt 1800 |
| tctttagcaa gagcagtata caaagatgct gatttgtatt tattagactc tccttttgga 1860 |
| tacctagatg ttttaacaga aaaagaaata tttgaaagct gtgtctgtaa actgatggct 1920 |
| aacaaaacta ggattttggt cacttctaaa atggaacatt taaagaaagc tgacaaaata 1980 |
| ttaattttga atgaaggtag cagctatttt tatgggacat tttcagaact ccaaaatcta 2040 |
| cagccagact ttagctcaaa actcatggga tgtgattctt tcgaccaatt tagtgcagaa 2100 |
| agaagaaatt caatcctaac tgagacctta caccgtttct cattagaagg agatgctcct 2160 |
| gtctcctgga cagaaacaaa aaaacaatct tttaaacaga ctggagagtt tggggaaaaa 2220 |
| aggaagaatt ctattctcaa tccaatcaac tctatacgaa aattttccat tgtgcaaaag 2280 |
| actcccttac aaatgaatgg catcgaagag gattctgatg agcctttaga gagaaggctg 2340 |
| tccttagtac cagattctga gcagggagag gcgatactgc ctcgcatcag cgtgatcagc 2400 |
| actggcccca cgcttcaggc acgaaggagg cagtctgtcc tgaacctgat gacacactca 2460 |
| gttaaccaag gtcagaacat tcaccgaaag acaacagcat ccacacgaaa agtgtcactg 2520 |
| gcccctcagg caaacttgac tgaactggat atatattcaa gaaggttatc tcaagaaact 2580 |
| ggcttggaaa taagtgaaga aattaacgaa gaagacttaa aggagtgcct ttttgatgat 2640 |
| atggagagca taccagcagt gactacatgg aacacatacc ttcgatatat tactgtccac 2700 |
| aagagcttaa tttttgtgct aatttggtgc ttagtaattt ttctggcaga ggtggctgct 2760 |
| tctttggttg tgctgtggct ccttggaaac actcctcttc aagacaaagg gaatagtact 2820 |
| catagtagaa ataacagcta tgcagtgatt atcaccagca ccagttcgta ttatgtgttt 2880 |
| tacatttacg tgggagtagc cgacactttg cttgctatgg gattcttcag aggtctacca 2940 |
| ctggtgcata ctctaatcac agtgtcgaaa attttacacc acaaaatgtt acattctgtt 3000 |
| cttcaagcac ctatgtcaac cctcaacacg ttgaaagcag gtgggattct taatagattc 3060 |
| tccaaagata tagcaatttt ggatgacctt ctgcctctta ccatatttga cttcatccag 3120 |
| ttgttattaa ttgtgattgg agctatagca gttgtcgcag ttttacaacc ctacatcttt 3180 |
| gttgcaacag tgccagtgat agtggctttt attatgttga gagcatattt cctccaaacc 3240 |
| tcacagcaac tcaaacaact ggaatctgaa ggcaggagtc caattttcac tcatcttgtt 3300 |
| acaagcttaa aaggactatg gacacttcgt gccttcggac ggcagcctta ctttgaaact 3360 |
| ctgttccaca aagctctgaa tttacatact gccaactggt tcttgtacct gtcaacactg 3420 |
| cgctggttcc aaatgagaat agaaatgatt tttgtcatct tcttcattgc tgttaccttc 3480 |
| atttccattt taacaacagg agaaggagaa ggaagagttg gtattatcct gactttagcc 3540 |
| atgaatatca tgagtacatt gcagtgggct gtaaactcca gcatagatgt ggatagcttg 3600 |
| atgcgatctg tgagccgagt ctttaagttc attgacatgc caacagaagg taaacctacc 3660 |
| aagtcaacca aaccatacaa gaatggccaa ctctcgaaag ttatgattat tgagaattca 3720 |
| cacgtgaaga aagatgacat ctggccctca gggggccaaa tgactgtcaa agatctcaca 3780 |
| gcaaaataca cagaaggtgg aaatgccata ttagagaaca tttccttctc aataagtcct 3840 |
| ggccagaggg tgggcctctt gggaagaact ggatcaggga agagtacttt gttatcagct 3900 |
| tttttgagac tactgaacac tgaaggagaa atccagatcg atggtgtgtc ttgggattca 3960 |
| ataactttgc aacagtggag gaaagccttt ggagtgatac cacagaaagt atttattttt 4020 |
| tctggaacat ttagaaaaaa cttggatccc tatgaacagt ggagtgatca agaaatatgg 4080 |
| aaagttgcag atgaggttgg gctcagatct gtgatagaac agtttcctgg gaagcttgac 4140 |
| tttgtccttg tggatggggg ctgtgtccta agccatggcc acaagcagtt gatgtgcttg 4200 |
| gctagatctg ttctcagtaa ggcgaagatc ttgctgcttg atgaacccag tgctcatttg 4260 |
| gatccagtaa cataccaaat aattagaaga actctaaaac aagcatttgc tgattgcaca 4320 |
| gtaattctct gtgaacacag gatagaagca atgctggaat gccaacaatt tttggtcata 4380 |
| gaagagaaca aagtgcggca gtacgattcc atccagaaac tgctgaacga gaggagcctc 4440 |
| ttccggcaag ccatcagccc ctccgacagg gtgaagctct ttccccaccg gaactcaagc 4500 |
| aagtgcaagt ctaagcccca gattgctgct ctgaaagagg agacagaaga agaggtgcaa 4560 |
| gatacaaggc tttagagagc agcataaatg ttgacatggg acatttgctc atggaattgg 4620 |
| agctcgtggg acagtcacct catggaattg gagctcgtgg aacagttacc tctgcctcag 4680 |
| aaaacaagga tgaattaagt ttttttttaa aaaagaaaca tttggtaagg ggaattgagg 4740 |
| acactgatat gggtcttgat aaatggcttc ctggcaatag tcaaattgtg tgaaaggtac 4800 |
| ttcaaatcct tgaagattta ccacttgtgt tttgcaagcc agattttcct gaaaaccctt 4860 |
| gccatgtgct agtaattgga aaggcagctc taaatgtcaa tcagcctagt tgatcagctt 4920 |
| attgtctagt gaaactcgtt aatttgtagt gttggagaag aactgaaatc atacttctta 4980 |
| gggttatgat taagtaatga taactggaaa cttcagcggt ttatataagc ttgtattcct 5040 |
| ttttctctcc tctccccatg atgtttagaa acacaactat attgtttgct aagcattcca 5100 |
| actatctcat ttccaagcaa gtattagaat accacaggaa ccacaagact gcacatcaaa 5160 |
| atatgcccca ttcaacatct agtgagcagt caggaaagag aacttccaga tcctggaaat 5220 |
| cagggttagt attgtccagg tctaccaaaa atctcaatat ttcagataat cacaatacat 5280 |
| cccttacctg ggaaagggct gttataatct ttcacagggg acaggatggt tcccttgatg 5340 |
| aagaagttga tatgcctttt cccaactcca gaaagtgaca agctcacaga cctttgaact 5400 |
| agagtttagc tggaaaagta tgttagtgca aattgtcaca ggacagccct tctttccaca 5460 |
| gaagctccag gtagagggtg tgtaagtaga taggccatgg gcactgtggg tagacacaca 5520 |
| tgaagtccaa gcatttagat gtataggttg atggtggtat gttttcaggc tagatgtatg 5580 |
| tacttcatgc tgtctacact aagagagaat gagagacaca ctgaagaagc accaatcatg 5640 |
| aattagtttt atatgcttct gttttataat tttgtgaagc aaaatttttt ctctaggaaa 5700 |
| tatttatttt aataatgttt caaacatata ttacaatgct gtattttaaa agaatgatta 5760 |
| tgaattacat ttgtataaaa taatttttat atttgaaata ttgacttttt atggcactag 5820 |
| tatttttatg aaatattatg ttaaaactgg gacaggggag aacctagggt gatattaacc 5880 |
| aggggccatg aatcaccttt tggtctggag ggaagccttg gggctgatcg agttgttgcc 5940 |
| cacagctgta tgattcccag ccagacacag cctcttagat gcagttctga agaagatggt 6000 |
| accaccagtc tgactgtttc catcaagggt acactgcctt ctcaactcca aactgactct 6060 |
| taagaagact gcattatatt tattactgta agaaaatatc acttgtcaat aaaatccata 6120 |
| catttgtgt 6129 |
| <200> SEQUENCE CHARACTERISTICS: |
| <210> SEQ ID NO 6 |
| <211> LENGTH: 1480 |
| <212> TYPE: PRT |
| <213> ORGANISM: Homo sapiens |
| <400> SEQUENCE: 6 |
| Met Gln Arg Ser Pro Leu Glu Lys Ala Ser Val Val Ser Lys Leu Phe |
| 1 5 10 15 |
| Phe Ser Trp Thr Arg Pro Ile Leu Arg Lys Gly Tyr Arg Gln Arg Leu |
| 20 25 30 |
| Glu Leu Ser Asp Ile Tyr Gln Ile Pro Ser Val Asp Ser Ala Asp Asn |
| 35 40 45 |
| Leu Ser Glu Lys Leu Glu Arg Glu Trp Asp Arg Glu Leu Ala Ser Lys |
| 50 55 60 |
| Lys Asn Pro Lys Leu Ile Asn Ala Leu Arg Arg Cys Phe Phe Trp Arg |
| 65 70 75 80 |
| Phe Met Phe Tyr Gly Ile Phe Leu Tyr Leu Gly Glu Val Thr Lys Ala |
| 85 90 95 |
| Val Gln Pro Leu Leu Leu Gly Arg Ile Ile Ala Ser Tyr Asp Pro Asp |
| 100 105 110 |
| Asn Lys Glu Glu Arg Ser Ile Ala Ile Tyr Leu Gly Ile Gly Leu Cys |
| 115 120 125 |
| Leu Leu Phe Ile Val Arg Thr Leu Leu Leu His Pro Ala Ile Phe Gly |
| 130 135 140 |
| Leu His His Ile Gly Met Gln Met Arg Ile Ala Met Phe Ser Leu Ile |
| 145 150 155 160 |
| Tyr Lys Lys Thr Leu Lys Leu Ser Ser Arg Val Leu Asp Lys Ile Ser |
| 165 170 175 |
| Ile Gly Gln Leu Val Ser Leu Leu Ser Asn Asn Leu Asn Lys Phe Asp |
| 180 185 190 |
| Glu Gly Leu Ala Leu Ala His Phe Val Trp Ile Ala Pro Leu Gln Val |
| 195 200 205 |
| Ala Leu Leu Met Gly Leu Ile Trp Glu Leu Leu Gln Ala Ser Ala Phe |
| 210 215 220 |
| Cys Gly Leu Gly Phe Leu Ile Val Leu Ala Leu Phe Gln Ala Gly Leu |
| 225 230 235 240 |
| Gly Arg Met Met Met Lys Tyr Arg Asp Gln Arg Ala Gly Lys Ile Ser |
| 245 250 255 |
| Glu Arg Leu Val Ile Thr Ser Glu Met Ile Glu Asn Ile Gln Ser Val |
| 260 265 270 |
| Lys Ala Tyr Cys Trp Glu Glu Ala Met Glu Lys Met Ile Glu Asn Leu |
| 275 280 285 |
| Arg Gln Thr Glu Leu Lys Leu Thr Arg Lys Ala Ala Tyr Val Arg Tyr |
| 290 295 300 |
| Phe Asn Ser Ser Ala Phe Phe Phe Ser Gly Phe Phe Val Val Phe Leu |
| 305 310 315 320 |
| Ser Val Leu Pro Tyr Ala Leu Ile Lys Gly Ile Ile Leu Arg Lys Ile |
| 325 330 335 |
| Phe Thr Thr Ile Ser Phe Cys Ile Val Leu Arg Met Ala Val Thr Arg |
| 340 345 350 |
| Gln Phe Pro Trp Ala Val Gln Thr Trp Tyr Asp Ser Leu Gly Ala Ile |
| 355 360 365 |
| Asn Lys Ile Gln Asp Phe Leu Gln Lys Gln Glu Tyr Lys Thr Leu Glu |
| 370 375 380 |
| Tyr Asn Leu Thr Thr Thr Glu Val Val Met Glu Asn Val Thr Ala Phe |
| 385 390 395 400 |
| Trp Glu Glu Gly Phe Gly Glu Leu Phe Glu Lys Ala Lys Gln Asn Asn |
| 405 410 415 |
| Asn Asn Arg Lys Thr Ser Asn Gly Asp Asp Ser Leu Phe Phe Ser Asn |
| 420 425 430 |
| Phe Ser Leu Leu Gly Thr Pro Val Leu Lys Asp Ile Asn Phe Lys Ile |
| 435 440 445 |
| Glu Arg Gly Gln Leu Leu Ala Val Ala Gly Ser Thr Gly Ala Gly Lys |
| 450 455 460 |
| Thr Ser Leu Leu Met Met Ile Met Gly Glu Leu Glu Pro Ser Glu Gly |
| 465 470 475 480 |
| Lys Ile Lys His Ser Gly Arg Ile Ser Phe Cys Ser Gln Phe Ser Trp |
| 485 490 495 |
| Ile Met Pro Gly Thr Ile Lys Glu Asn Ile Ile Phe Gly Val Ser Tyr |
| 500 505 510 |
| Asp Glu Tyr Arg Tyr Arg Ser Val Ile Lys Ala Cys Gln Leu Glu Glu |
| 515 520 525 |
| Asp Ile Ser Lys Phe Ala Glu Lys Asp Asn Ile Val Leu Gly Glu Gly |
| 530 535 540 |
| Gly Ile Thr Leu Ser Gly Asp Gln Arg Ala Arg Ile Ser Leu Ala Arg |
| 545 550 555 560 |
| Ala Val Tyr Lys Asp Ala Asp Leu Tyr Leu Leu Asp Ser Pro Phe Gly |
| 565 570 575 |
| Tyr Leu Asp Val Leu Thr Glu Lys Glu Ile Phe Glu Ser Cys Val Cys |
| 580 585 590 |
| Lys Leu Met Ala Asn Lys Thr Arg Ile Leu Val Thr Ser Lys Met Glu |
| 595 600 605 |
| His Leu Lys Lys Ala Asp Lys Ile Leu Ile Leu Asn Glu Gly Ser Ser |
| 610 615 620 |
| Tyr Phe Tyr Gly Thr Phe Ser Glu Leu Gln Asn Leu Gln Pro Asp Phe |
| 625 630 635 640 |
| Ser Ser Lys Leu Met Gly Cys Asp Ser Phe Asp Gln Phe Ser Ala Glu |
| 645 650 655 |
| Arg Arg Asn Ser Ile Leu Thr Glu Thr Leu His Arg Phe Ser Leu Glu |
| 660 665 670 |
| Gly Asp Ala Pro Val Ser Trp Thr Glu Thr Lys Lys Gln Ser Phe Lys |
| 675 680 685 |
| Gln Thr Gly Glu Phe Gly Glu Lys Arg Lys Asn Ser Ile Leu Asn Pro |
| 690 695 700 |
| Ile Asn Ser Ile Arg Lys Phe Ser Ile Val Gln Lys Thr Pro Leu Gln |
| 705 710 715 720 |
| Met Asn Gly Ile Glu Glu Asp Ser Asp Glu Pro Leu Glu Arg Arg Leu |
| 725 730 735 |
| Ser Leu Val Pro Asp Ser Glu Gln Gly Glu Ala Ile Leu Pro Arg Ile |
| 740 745 750 |
| Ser Val Ile Ser Thr Gly Pro Thr Leu Gln Ala Arg Arg Arg Gln Ser |
| 755 760 765 |
| Val Leu Asn Leu Met Thr His Ser Val Asn Gln Gly Gln Asn Ile His |
| 770 775 780 |
| Arg Lys Thr Thr Ala Ser Thr Arg Lys Val Ser Leu Ala Pro Gln Ala |
| 785 790 795 800 |
| Asn Leu Thr Glu Leu Asp Ile Tyr Ser Arg Arg Leu Ser Gln Glu Thr |
| 805 810 815 |
| Gly Leu Glu Ile Ser Glu Glu Ile Asn Glu Glu Asp Leu Lys Glu Cys |
| 820 825 830 |
| Leu Phe Asp Asp Met Glu Ser Ile Pro Ala Val Thr Thr Trp Asn Thr |
| 835 840 845 |
| Tyr Leu Arg Tyr Ile Thr Val His Lys Ser Leu Ile Phe Val Leu Ile |
| 850 855 860 |
| Trp Cys Leu Val Ile Phe Leu Ala Glu Val Ala Ala Ser Leu Val Val |
| 865 870 875 880 |
| Leu Trp Leu Leu Gly Asn Thr Pro Leu Gln Asp Lys Gly Asn Ser Thr |
| 885 890 895 |
| His Ser Arg Asn Asn Ser Tyr Ala Val Ile Ile Thr Ser Thr Ser Ser |
| 900 905 910 |
| Tyr Tyr Val Phe Tyr Ile Tyr Val Gly Val Ala Asp Thr Leu Leu Ala |
| 915 920 925 |
| Met Gly Phe Phe Arg Gly Leu Pro Leu Val His Thr Leu Ile Thr Val |
| 930 935 940 |
| Ser Lys Ile Leu His His Lys Met Leu His Ser Val Leu Gln Ala Pro |
| 945 950 955 960 |
| Met Ser Thr Leu Asn Thr Leu Lys Ala Gly Gly Ile Leu Asn Arg Phe |
| 965 970 975 |
| Ser Lys Asp Ile Ala Ile Leu Asp Asp Leu Leu Pro Leu Thr Ile Phe |
| 980 985 990 |
| Asp Phe Ile Gln Leu Leu Leu Ile Val Ile Gly Ala Ile Ala Val Val |
| 995 1000 1005 |
| Ala Val Leu Gln Pro Tyr Ile Phe Val Ala Thr Val Pro Val Ile Val |
| 1010 1015 1020 |
| Ala Phe Ile Met Leu Arg Ala Tyr Phe Leu Gln Thr Ser Gln Gln Leu |
| 1025 1030 1035 1040 |
| Lys Gln Leu Glu Ser Glu Gly Arg Ser Pro Ile Phe Thr His Leu Val |
| 1045 1050 1055 |
| Thr Ser Leu Lys Gly Leu Trp Thr Leu Arg Ala Phe Gly Arg Gln Pro |
| 1060 1065 1070 |
| Tyr Phe Glu Thr Leu Phe His Lys Ala Leu Asn Leu His Thr Ala Asn |
| 1075 1080 1085 |
| Trp Phe Leu Tyr Leu Ser Thr Leu Arg Trp Phe Gln Met Arg Ile Glu |
| 1090 1095 1100 |
| Met Ile Phe Val Ile Phe Phe Ile Ala Val Thr Phe Ile Ser Ile Leu |
| 1105 1110 1115 1120 |
| Thr Thr Gly Glu Gly Glu Gly Arg Val Gly Ile Ile Leu Thr Leu Ala |
| 1125 1130 1135 |
| Met Asn Ile Met Ser Thr Leu Gln Trp Ala Val Asn Ser Ser Ile Asp |
| 1140 1145 1150 |
| Val Asp Ser Leu Met Arg Ser Val Ser Arg Val Phe Lys Phe Ile Asp |
| 1155 1160 1165 |
| Met Pro Thr Glu Gly Lys Pro Thr Lys Ser Thr Lys Pro Tyr Lys Asn |
| 1170 1175 1180 |
| Gly Gln Leu Ser Lys Val Met Ile Ile Glu Asn Ser His Val Lys Lys |
| 1185 1190 1195 1200 |
| Asp Asp Ile Trp Pro Ser Gly Gly Gln Met Thr Val Lys Asp Leu Thr |
| 1205 1210 1215 |
| Ala Lys Tyr Thr Glu Gly Gly Asn Ala Ile Leu Glu Asn Ile Ser Phe |
| 1220 1225 1230 |
| Ser Ile Ser Pro Gly Gln Arg Val Gly Leu Leu Gly Arg Thr Gly Ser |
| 1235 1240 1245 |
| Gly Lys Ser Thr Leu Leu Ser Ala Phe Leu Arg Leu Leu Asn Thr Glu |
| 1250 1255 1260 |
| Gly Glu Ile Gln Ile Asp Gly Val Ser Trp Asp Ser Ile Thr Leu Gln |
| 1265 1270 1275 1280 |
| Gln Trp Arg Lys Ala Phe Gly Val Ile Pro Gln Lys Val Phe Ile Phe |
| 1285 1290 1295 |
| Ser Gly Thr Phe Arg Lys Asn Leu Asp Pro Tyr Glu Gln Trp Ser Asp |
| 1300 1305 1310 |
| Gln Glu Ile Trp Lys Val Ala Asp Glu Val Gly Leu Arg Ser Val Ile |
| 1315 1320 1325 |
| Glu Gln Phe Pro Gly Lys Leu Asp Phe Val Leu Val Asp Gly Gly Cys |
| 1330 1335 1340 |
| Val Leu Ser His Gly His Lys Gln Leu Met Cys Leu Ala Arg Ser Val |
| 1345 1350 1355 1360 |
| Leu Ser Lys Ala Lys Ile Leu Leu Leu Asp Glu Pro Ser Ala His Leu |
| 1365 1370 1375 |
| Asp Pro Val Thr Tyr Gln Ile Ile Arg Arg Thr Leu Lys Gln Ala Phe |
| 1380 1385 1390 |
| Ala Asp Cys Thr Val Ile Leu Cys Glu His Arg Ile Glu Ala Met Leu |
| 1395 1400 1405 |
| Glu Cys Gln Gln Phe Leu Val Ile Glu Glu Asn Lys Val Arg Gln Tyr |
| 1410 1415 1420 |
| Asp Ser Ile Gln Lys Leu Leu Asn Glu Arg Ser Leu Phe Arg Gln Ala |
| 1425 1430 1435 1440 |
| Ile Ser Pro Ser Asp Arg Val Lys Leu Phe Pro His Arg Asn Ser Ser |
| 1445 1450 1455 |
| Lys Cys Lys Ser Lys Pro Gln Ile Ala Ala Leu Lys Glu Glu Thr Glu |
| 1460 1465 1470 |
| Glu Glu Val Gln Asp Thr Arg Leu |
| 1475 1480 |
| Patent | Priority | Assignee | Title |
| 10421965, | Sep 25 2013 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
| 10450566, | Sep 25 2013 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
| 10744154, | May 16 2006 | Galectin Therapeutics, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 6878751, | Oct 19 2000 | Imperial College of Science Technology and Medicine; IMPERIAL COLLEGE INNOVATIONS LIMITED | Administration of resveratrol to treat inflammatory respiratory disorders |
| 7335683, | Oct 16 1997 | Children's Hospital & Research Center at Oakland | Compositions and methods for cystic fibrosis therapy |
| 7498047, | Oct 31 2002 | National Jewish Medical and Research Center | Methods for treatment of thiol-containing compound deficient conditions |
| 7718694, | Oct 16 1997 | CHILDREN S HOSPITAL & RESEARCH INSTITUTE AT OAKLAND; CHILDREN S HOSPITAL & RESEARCH CENTER AT OAKLAND | Compositions and methods for therapy for diseases characterized by defective chloride transport |
| 7790762, | Oct 31 2002 | National Jewish Health | Compounds and methods for thiol-containing compound efflux and cancer treatment |
| 7893252, | Sep 08 2003 | GALECTIN THERAPEUTICS INC | Selectively depolymerized galactomannan polysaccharide |
| 8017649, | Mar 11 2005 | WOODMAN, OWEN LLEWELLYN | Flavonoid compounds and uses thereof |
| 8138158, | Oct 16 1997 | Children's Hospital & Research Center at Oakland | Compositions and methods for therapy for diseases characterized by defective chloride transport |
| 8236780, | May 16 2006 | GALECTIN THERAPEUTICS INC | Galactose—pronged polysaccharides in a formulation for antifibrotic therapies |
| 8367638, | May 16 2006 | Galectin Therapeutics Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 8722645, | May 16 2006 | Galectin Therapeutics Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 8883010, | Dec 04 2008 | The University of Akron | Polymer composition with phytochemical and dialysis membrane formed from the polymer composition |
| 9062022, | Dec 04 2008 | The University of Akron | Polymer composition and dialysis membrane formed from the polymer composition |
| 9200090, | May 16 2006 | Galectin Therapeutics, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| 9339515, | Feb 20 2013 | GALECTIN THERAPEUTICS, INC | Method for treatment of pulmonary fibrosis |
| 9956236, | Feb 07 2011 | Cornell University | Methods for increasing immune responses using agents that directly bind to and activate IRE-1 |
| 9957506, | Sep 25 2013 | Cornell University | Compounds for inducing anti-tumor immunity and methods thereof |
| Patent | Priority | Assignee | Title |
| 5972995, | Oct 16 1997 | CHILDREN S HOSPITAL & RESEARCH CENTER AT OAKLAND | Compositions and methods for cystic fibrosis therapy |
| JP87105816, | |||
| JP93330545, | |||
| JP94277493, | |||
| JP95135875, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 16 1998 | Children's Hospital Oakland Research Institute | (assignment on the face of the patent) | / | |||
| Jan 04 1999 | FISCHER, HORST | CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009743 | /0151 | |
| Jan 04 1999 | ILLEK, BEATE | CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 009743 | /0151 | |
| Jan 30 2006 | CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE | CHILDREN S HOSPITAL & RESEARCH CENTER AT OAKLAND | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 017186 | /0282 |
| Date | Maintenance Fee Events |
| Jun 13 2005 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Jun 24 2005 | ASPN: Payor Number Assigned. |
| Jun 11 2009 | M2552: Payment of Maintenance Fee, 8th Yr, Small Entity. |
| Mar 01 2013 | M2553: Payment of Maintenance Fee, 12th Yr, Small Entity. |
| Date | Maintenance Schedule |
| Dec 11 2004 | 4 years fee payment window open |
| Jun 11 2005 | 6 months grace period start (w surcharge) |
| Dec 11 2005 | patent expiry (for year 4) |
| Dec 11 2007 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Dec 11 2008 | 8 years fee payment window open |
| Jun 11 2009 | 6 months grace period start (w surcharge) |
| Dec 11 2009 | patent expiry (for year 8) |
| Dec 11 2011 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Dec 11 2012 | 12 years fee payment window open |
| Jun 11 2013 | 6 months grace period start (w surcharge) |
| Dec 11 2013 | patent expiry (for year 12) |
| Dec 11 2015 | 2 years to revive unintentionally abandoned end. (for year 12) |